A - Z List of Registered Resources
This is a list of all the registered resources in the Directory. Scroll through the list or use the filter box to restrict the resources displayed. If you would like to search for specific collections or capabilities based on additional criteria (such as disease), visit our Directory home page.
| Name | County | Description | |
|---|---|---|---|
| Acute Pancreatitis Research Biobank | Merseyside | The biobank contains frozen samples of whole blood (for RNA and DNA extraction), plasma, serum and urine from patients diagnosed with acute pancreatitis, collected over a number of timepoints from diagnosis. | |
| Add-Aspirin Translational Samples | Greater London | Collection of whole blood samples for plasma and DNA extraction and formulin-fixed paraffin-embedded (FFPE) tumour samples | |
| Alliance for Cancer Early Detection (ACED) Cohort | Cambridgeshire | This project aims to provide baseline and longitudinal information on patients attending the Early Detection research clinic which tests new approaches for identification of individuals at high risk for cancer. When patients attend this clinic we plan to collect demographic, physiological and epidemiological information, and store biological samples (e.g. DNA, blood, blood derivatives and urine) from a minimum of 200 adults per year. Many of these individuals will be volunteers and this cohort will be valuable for researchers to establish biomarker thresholds for healthy individuals. This cohort will also allow us to better understand risk factors for cancer and explore techniques and methodologies to detect cancer at an earlier stage. Participants will be consented so that we maintain a population cohort enriched for risks of specific cancers and track disease outcomes. These participants may also be invited for further studies and longitudinal sampling with the aim that these participants and/or samples can be accessed for other genetic biomedical studies and clinical trials including first in humans. | |
| Anthony Nolan Research Tissue Bank | Nottinghamshire | Anthony Nolan Research Tissue Bank is part of the Anthony Nolan Cell and Gene Therapy services. We are dedicated to saving and improving the lives of patients in need, now and in the future, and we recognize the important role research plays in saving and improving the lives of patients. Through the Research Tissue Bank, we aim to facilitate ethical research through the provision of healthy donor material. The Research Tissue Bank has the ability to provide Umbilical Cord blood, Umbilical Cord Tissue, Adult peripheral blood stem cells, Adult Leacocytes, Adult whole blood. Most samples types are availble fresh or frozen and in multiple formats and sizes. | |
| Apheresis MNC Collection | North Lanarkshire | A cell bank of allogeneic γδ T cells required to ensure that an adequate supply of γδ T cells is available for research and development purposes as well as to conduct future clinical trials using γδ T cells (unmodified or modified) as IMP. | |
| Archival Cardiothoracic tissue and biofluid research bank | Lancashire | An archival Cardiothoracic tissue and biofluid research bank containing fresh and formalin fixed paraffin embedded tissue blocks (cancer and non cancer), urine, saliva and blood. | |
| Archival gastro-intestinal tissue, blood, saliva and urine collection | Lancashire | Tissue bank contains paraffin blocks, a limited number of frozen tissue samples, frozen buffy coat, plasma and serum, frozen urine and frozen saliva. | |
| Archival genito-urinary tissue, blood, urine and saliva collection | Lancashire | Archival genito-urinary tissue, blood, urine and saliva collection | |
| Archival nervous system tissue and blood collection | Lancashire | Archival nervous system tissue and blood collection | |
| Arden Tissue Bank | Warwickshire | Arden Tissue Bank operates under a Human Tissue Authority post mortem licence within a district general hospital. The biobank has generic ethical approval, and is able to collect tissues prospectively across a wide range of tissue types. In addition the biobank has access to the full pathological archive across three hospital sites. The cellular pathology archive is searchable by SNOMED coding for selection of specific conditions of interest. The cellular pathology archive alone totals almost 2 million blocks, with full patient data available from 2005 including pathology reports. | |
| ARIEL ctDNA samples | West Midlands | ctDNA samples from patients within the NIHR funded ARIEL trial | |
| ARISTOTLE Trial | Greater London | ARISTOTLE is a multicentre, phase III, randomised trial comparing standard neoadjuvant chemoradiotherapy (CRT) of oral capecitabine and radiotherapy versus standard CRT with the addition of irinotecan. 600 patients with MRI defined locally advanced, non-metastatic rectal cancer will be allocated in a 1:1 ratio to the two treatment arms. Samples collected for translational research as part of the trial: (i) archival tumour tissue blocks (from diagnostic biopsy), (ii) tumour tissue blocks and normal mucosal tissue from tumour resection (post CRT), (iii) plasma for circulating tumour DNA (ctDNA), (iv) buffy coat for germline DNA. | |
| Asp-PSC samples | Biological samples will be collected for patients with primary sclerosing cholangitis (PSC) and Inflmattory Bowel Diseas (IBD) for the trial called Effect of Aspirin on Reducing Cancer & Improving Outcomes in Primary Sclerosing Cholangitis (Asp-PSC). Samples will be colleted as screening and every 6 months for five years for 968 patients. The following samples will be collected: 1. 6ml of whole blood genomic DNA (Screening only) 2. 4ml of plasma for ctDNA (Screening and every 6 months) 3. 7 cyrovials of plasma (Screening and every 6 months) 4. 4 cyrovials of serum (Screening and every 6 months) 5. 8 cyrovials of urine (Screening and every 6 months) | ||
| AstraZeneca | Cambridgeshire | AstraZeneca has a global biobank network storing human biological samples from AZ sponsored clinical trials, collaborations and also procured samples. These samples span the following main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, Respiratory, Inflammation and AutoImmunity, Neuroscience. There are over 1 million samples logged in the AstraZeneca Biobank Application (ABBA). Work needs to be done to identify which specific sample sets can be shared (both from closed clinical trials and from those that were commercially acquired), by establishing those that have the appropriate consent level and data available and to get the necessary approvals in place for to access these samples. | |
| Avon Longitudinal Study of Parents and Children (ALSPAC) | Bristol | The Avon Longitudinal Study of Parents and Children (ALSPAC) is a longitudinal cohort study which has been charting the health of 14,500 families in the Bristol area since the early 1990s in order to improve the health of future generations. The study is also known as the Children of the 90s study. The ALSPAC biobank is covered by research tissue bank ethical approval REC reference 23/SW/0058 Mothers were recruited during pregnancy. The children born in 1991 and 1992 (known as ALSPAC-G1) and their mothers and fathers (G0) have been followed since. A large amount of phenotypic and environmental exposure data has been collected via questionnaires, research clinics and record linkage. The study website contains details of all the data that is available through a searchable data dictionary. Many of the original participants are now becoming parents and we are recruiting the next generation of children (ALSPAC-G2). Therefore ALSPAC is able to make a completely unique contribution to health science, by being able to understand how health, well-being and disease are passed through families. Samples have been collected throughout the participants lives and include DNA, lymphoblastoid cell lines, blood, urine, saliva, placentas, hair, nails and milk teeth. A large amount of omics data has been generated from samples including genetic, epigenetic and metabolomic data. The samples and data form a resource for the scientific community for projects which comply with our access conditions as outlined in our access policy. This can be found on our study website. All data generated from samples must be returned to ALSPAC for inclusion in the data resource and will be made available to other researchers. Study participants can be recalled for specific sample and/or data collection exercises eg for recall by genotype, phenotype or exposure studies. Such studies will be designed on a case by case basis and will be subject to appropriate ethical approval. Please contact the laboratory (email addresses in contact section) to discuss sample requirements. Publications can be found at https://www.bristol.ac.uk/alspac/researchers/publications/ | |
| Baby Bio Bank | Greater London | The Baby Bio Bank is a collection of over 50,000 biological samples and medical data collected fromover 2,500 pregnancies affected by recurrent miscarriage, preterm birth, intrauterine growth restriction and pre-eclampsia. We have also collected samples from pregnancies complicated with other medical conditions such as Diabetes, high BMI, hypertension, IVF, twin and a cohort of samples from uncomplicated pregnanciess. We hold DNA, RNA, serum, plasma and whole blood from both parents and urine from the mother. From the baby we hold cord blood, cord, placental tissues and membranes, DNA and placental RNA. The samples are avaliable for research into pregnancy complications. | |
| Barts Bioresourse | Greater London | The purpose of the Bart’s Bioresource was to establish a repository of generic consented patients clinically managed by Cardiac Services at Bart’s Health NHS Trust. In addition to this the consent includes the donation of human blood, tissue donation (e.g. atrial appendage or pulmonary vein tissue) for the purpose of establishing a biobank of samples for use in cardiac disease research. The patients are informed that “The purpose of the Bart’s Bioresource is to allow research into diseases of the heart and circulation (cardiovascular research). The Bart’s Bioresource is supported by the National Institute for Health Research, which is part of the National Health Service (NHS). The Bart’s Bioresource will be very valuable because it will help us to find new ways of identifying, treating and preventing diseases of the heart and circulation.” | |
| Barts Cancer Institute Breast Tissue Bank | Greater London | This ground breaking initiative will see the Barts Cancer Institute and 4 other centres around the country working together as one national resource, to house the multi-million pound Breast Cancer Now Tissue Bank. Professor Louise Jones and a dedicated team head up the Tissue bank in the Barts Cancer Institute. The tissue bank includes a dedicated cell culture team, and has just established the Metastatic Bank including a Rapid Autopsy Programme. In the coming years we will see the benefits to people with breast cancer, as research using tissues from the Bank will lead to new treatments which have the potential to save the lives of many thousands of people with this disease. | |
| Barts CTU | Greater London | We conduct research into the prevention of cancer with particular focus on preventive therapy and screening. We are involved in clinical trials and epidemiology. | |
| Barts Diabetic Kidney Centre Registry & BioBank | Greater London | BioBank focused on patients with diabetes and kidney disease with controls | |
| Barts Gynae Tissue Bank | Greater London | The purpose of the Barts Gynae Tissue Bank is to collect, store and share high quality tissue for translational research into gynaecological cancers. We collect gynaecological tissues, ascites, blood and urine that have been obtained during standard diagnostic and therapeutic procedures and are surplus to pathological diagnostic requirements. Tissues are collected from both primary and metastatic gynaecological cancer as well as from non-malignant tissues obtained in the course of standard investigation and treatment. The Barts Gynae Tissue Bank wishes to share the collection with academic researchers undertaking high quality research. | |
| Barts Pancreas Tissue Bank | Greater London | Pancreatic diseases can be very difficult to diagnose and monitor because of the location of the pancreas deep within the abdomen. Also, with the current range of tests it may not be possible (in some cases) to tell the difference between pancreatitis (inflammation of the pancreas) and other conditions such as cancer of the pancreas without surgery and direct biopsy of tissues from this organ. This project is aimed to create a research tissue bank (explained below), specifically for pancreatic diseases. It will help researchers conduct a range of investigations in the near future. Thus this research project aims to develop new diagnostic tests as well as treatments for patients with pancreatic disease. | |
| Bath Spondyloarthritis Biobank | Avon | Spondyloarthropathy (SpA) is a chronic inflammatory rheumatic disease principally affecting the spine leading to progressive spinal deformity. We have been collecting data on our Spondyloarthritis patients since the 1980's. We also have Serum and DNA stored for a small proportion of our patients | |
| Biliary Tract Cancer Virtual Tissue Bank | Greater London | We plan to create a national virtual tissue bank of tissue samples from Biliary Tract Cancer patients who have participated in a clinical trial, and their associated prospectively collected clinical trial data, for high quality, peer reviewed and ethically approved research. Samples will be collected and stored in two separate Biobanks: 1) UCL/UCLH Biobank for Studying Health and Disease 2) Manchester Cancer Research Centre (MCRC) Biobank Central Coordination of the BTC VTB will be conducted by CR UK & UCL Cancer Trials Centre (UCL CTC). To gain access to the samples Researchers will be required to submit to the BTC VTB Scientific Review Committee (SRC), via the UKCRC directory in the first instance. If approved by the SRC it will then be submitted to the Access Committee for each relevant Biobank. Samples will be collected from the following trials: • ABC-01 • ABC-02 • ABC-03 • ABC-04 • ABC-07 • Photostent-02 • ACTICCA-1 | |
| Biobank for patients with retinal degenerations & dystrophies | Northumberland | Outer retinal disease is the most common cause of blindness in the UK. It can be caused by a variety of single gene defects, including conditions such as retinitis pigmentosa which often result in early onset blindness in childhood, whilst the risk of age related macular degeneration is caused by a variety of complex multigene defects causing visual loss in later life. Treatments are evolving for both diseases but the underlying pathogenesis and treatment of these diseases remains elusive. We have formed the biobank as a repository of fibroblasts (from skin and hair samples) from patients with a variety of retinal diseases that could then be used with induced pluripotent stem cell technology to investigate causes and new treatments for these conditions. | |
| BioGrad Biobank | Merseyside | To be updated - full details to follow | |
| Biology of the Human Uterus in Pregnancy and Disease Tissue Bank | Cambridgeshire | This tissue bank was established to support the research of members of the Centre for Trophoblast Research at the University of Cambridge into maternal-fetal interactions during pregnancy. Because of the limited number of samples available it is not possible to supply tissues to external researchers unless in the context of a collaborative project with a member of the Centre. | |
| BioPTIC (Biomarkers for Pediatric Transplantation In Children) | Greater London | The aim of BioPTIC is to establish a database of biological tissue from children with solid organ transplants, whereby biomarkers predictive of transplant rejection could be studied, with the goal that a biomarker can be found and used to diagnose paediatric transplant rejection, as an alternative or as an adjunct to a transplant biopsy, which is the current gold standard. | |
| BioResource in Adult Infectious Diseases | Greater London | The Bioresource for Adult Infectious Diseases (BioAID) is a collaborative project between multiple NHS Hospitals in partnership with closely affiliated UK Universities. BioAID aims to collect biological samples and clinical information from 10,000 episodes in which patients present to hospital with a suspected infectious disease. Participants will be asked to give consent to have their samples and clinical information collected within BioAID. The samples will be used to obtain RNA and serum from blood samples at various time points during the illness. In addition, the samples will be used to obtain the participants DNA and the microbial organism causing the illness where possible. This will provide an invaluable BioResource to evaluate new strategies for diagnosis of infectious diseases and predicting the outcome of specific diseases in individual patients. BioAID will also help to establish the framework for research sampling and data collection to complement existing studies in infectious diseases, and inform the design of new studies as well as provision of NHS services for infectious diseases. The samples and clinical information collected within BioAID will be held within the participating sites. Access to these collections will be provided to research investigators under the terms of material and data sharing agreements. Identifiable patient information will not be disclosed. | |
| Birmingham Children's Hospital Liver Tissue Bank | West Midlands | A collection of blood and tissue samples from patients that have been treated at the Liver Unit at Birmingham Children's Hospital | |
| Birmingham Dentistry Research and Teaching Biorepository | West Midlands | The dentistry research and teaching biorepository (DRTB) is a collection of human tissue and other biological material that is stored and released for potential research use and is not restricted to a specific project with ethical approval. Furthermore, the DRTB is a collection of data, usually associated with a donor or donor tissue to be used independently for research or in conjunction with tissue analysis data to contextualize the results. Finally, the DRTB is a repository for anonymized tissues and waste tissues to be used for the education of future dentists, researchers and scientists in the skills and specialist procedures of their respective disciplines. | |
| Blood Cancer UK Childhood Leukaemia Cell Bank | North Yorkshire | CellBank has recently merged with the CCLG Tissue Bank to form VIVO Biobank. A new entry for the VIVO Biobank may be found in this directory. Historic access requests to CellBank are still on this page. Publications are also found on this page pending transfer. The Blood Cancer UK Childhood Leukaemia Cell Bank is a national collection of samples from children and young people with paediatric haematological malignancies. It is very well annotated with demographic, clinical and genetic features. This annotation enables identification and curation of very rare subgroups. There is a range of sample types including viable cells and DNA from bone marrow, plasma and CSF supporting many different types of project. The Bank is open to international as well as UK-based researchers where at least one of the investigators is based at a UK university or NHS institution. Applications are reviewed rapidly by an independent review panel. Our team can give help and advice at all stages of the application from initial enquiry to dispatch of samples. The Bank also holds a collection of HLA typed cord blood which are subject to the same review process. | |
| Born in Bradford | West Yorkshire | Born in Bradford aims to find out what keeps families healthy and happy by tracking the lives of over 40,000 Bradfordians. We use our findings to develop new and practical ways to work with families and health professionals to improve the health and wellbeing of our communities. | |
| Born in Bradford | West Yorkshire | Born in Bradford aims to find out what keeps families healthy and happy by tracking the lives of over 40,000 Bradfordians. We use our findings to develop new and practical ways to work with families and health professionals to improve the health and wellbeing of our communities. | |
| BOXIT | Surrey | A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder | |
| BRAIN UK | Hampshire | BRAIN UK is a virtual brain bank which provides access to tissue already available in NHS archives as well as the provision of generic ethics. The BRAIN UK network includes 23 of 24 Neuropathology Centres across the UK. | |
| Breast Cancer Now Tissue Bank | Greater London | The Breast Cancer Now Tissue Bank (BCNTB) is the UK’s first ever national breast cancer tissue bank and provides high-quality, biomaterials and data from breast cancer patients and individuals without breast cancer. The BCNTB provides the breadth of materials needed for breast cancer research, ranging from serum samples, through frozen and fixed tissue samples to isolated breast cell populations. We help the research community to raise the standard of breast cancer research and facilitate the coordinated translation of scientific findings into the clinical setting. Breast Cancer Now provides funding to four leading research institutions to run the BCNTB. All centres (listed below) are licensed by the Human Tissue Authority: • Barts Cancer Institute, Queen Mary University of London (Lead Operational Centre) • University of Aberdeen • University of Sheffield • University of East Anglia | |
| Bristol Biobank | Gloucestershire | The Bristol Biobank (funded by the David Telling Charitable Trust with stakeholders from the University of Bristol and University Hospitals NHS Foundation Trust) stores samples collected from patients and healthy volunteers for use in biomedical research. Researchers in Bristol and beyond can apply to use these samples in their research. The collection of a wide range of samples will provide a platform for research into complex conditions. Researchers may request to deposit samples into the Biobank following the end of a NHS Research Ethics Committee approved study. Consent must have been taken using study specific documentation for the storage and use of these samples in research beyond the study. The Bristol Biobank team will also be happy to receive applications to deposit samples for specific projects you wish to set-up using Biobank permissions and documentation. The Bristol Biobank is licensed by the Human Tissue Authority (licence 12512) to store human tissue for research and has ethics approval from Wales Research Ethics Committee 3 as a research tissue bank to collect and issue biomaterials for biomedical research across a range of therapeutic areas. | |
| Bristol Dental School Saliva Bank | Bristol | Whole human saliva is collected from donors at the Bristol Dental School at the University of Bristol. | |
| c-TRAK TN | Surrey | c-TRAK TN: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with high risk early stage triple negative breast cancer | |
| Cambridge Blood and Stem Cell Biobank | Cambridgeshire | Cambridge Blood and Stem Cell Biobank collects and curates blood and blood-product derived samples from normal individuals and patients with blood and related malignancies, with particular emphasis on accessibility to purified tumour and stem cell populations from these samples. Set up in 2009, by 2016 the bank already contains over 12,000 samples, 70% from patients enrolled on research studies and clinical trials, and the remainder from cord blood donors. We specialise in bespoke fresh specimen collections for research into clonal blood cell disorders, autoimmune disorders and normal blood cell development. | |
| Cancer Group CTR Cardiff trials | Cardiff | Centre for Trials Research Cardiff University. Trial sample collections | |
| Cancer Research UK | Greater London | An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations, including Common Cancers with Rare Actionable Alterations | |
| Cancer Tissue Bank | Greater London | Controlling metastasis is an essential requirement for cancer management. The current model systems pay scant attention to human biology due to scarcity of evaluable patient samples. We propose an expansion of the tissue banks at the Barts Cancer Institute to include the collection of metastasis from a variety of primary tumours as well as distinct metastatic sites for use in laboratory research. This will facilitate identification targets to control tumour spread and develop novel biomarkers. | |
| CANDAS | Greater London | The Clinical Neurological Disease Biobank and Neurogenetics Research Study (CANDAS) bank is a clinical and biological database which will record the disease phenotype and facilitate the identification of genetic factors that: i.) predispose to neurologic disease; ii.) modulate the disease phenotype, leading to clinical differences and/or variation in drug responsiveness; and iii.) are responsible for rarer forms of Mendelian disease. We collect and store DNA samples, fibroblast cell lines, induced pluripotent cell lines and whole blood to enable this research. | |
| Cardamon Clinical Trial Samples | Greater London | Samples taken as part of the Cardamon clinical trial | |
| Cardiff School of Dentistry Tooth Bank | Cardiff | Collection of both deciduous and permanent teeth. Collection of fresh teeth for extraction of pulpal cells can be arranged. | |
| Cardiff University Biobank | Cardiff | The Cardiff University Biobank is a centralised biobanking facility sited at the University Hospital of Wales. We offer high quality human biosamples for research undertaken for patient and public benefit to academic and commercial organisations. We have established collections from a number of different disease areas and welcome approaches to initiate new collections not already established within the facility. The biobank also welcome applications to deposit samples from completed research projects or clinical trails. | |
| CASPS: A Phase II trial of Cediranib in ASPS patients | Surrey | CASPS is a two-arm, randomised, double-blind, placebo-controlled, Phase II trial of cediranib in ASPS patients. The primary objective is to evaluate the efficacy of cediranib by measuring the percentage change in the sum of target marker lesion diameters from randomisation to week 24 compared to placebo. Secondary objectives include: progression-free survival, overall survival and safety and tolerability of cediranib in ASPS patients. Tissue markers of tumour response, circulating markers of angiogenesis, and changes in circulating endothelial cells/precursor cells in response to cediranib will be explored. Thirty six patients with progressive, metastatic, histologically confirmed ASPS will be recruited. Patients will be randomised to 24 weeks of blinded cediranib or placebo, after which treatment will be unblinded and all patients offered open-label cediranib until objective disease progression, or death if sooner. | |
| Central England Haemato-oncology and oncology Research Biobank (CEHRB) | West Midlands | The Central England Haemato-Oncology and oncology Research BioBank (CEHRB) predominantly stores excess material from haemato-oncology and oncology samples referred for diagnostic testing and disease monitoring at the West Midlands Regional Genetics Laboratory (WMRGL). Haemato-oncology samples are stored at presentation and throughout the disease course, including at remission and relapse. In addition CEHRB stores haemato-oncology and oncology samples which are specifically taken for the biobank, usually in response to a specific project. CEHRB is housed within the WMRGL which is accredited by United Kingdom Accreditation Services to ISO15189:2012. The WMRGL serves a population of about 6 million and is the largest UK NHS genetics lab. Due to the large patient population CEHRB is able to collate sufficient research material from all classifications of neoplastic haematological disorders including those that are rare. | |
| Centre for Longitudinal Studies (CLS) | Greater London | All samples currently in the tissue bank were collected from three unique and powerful longitudinal cohort studies run by the Centre for Longitudinal Studies at the UCL Institute of Education: the 1958 birth cohort (also known as the National Child Development Study), the 1970 British Cohort Study and the Millenium Cohort Study. The 1958 birth cohort study (NCDS) recruited over 17,000 individuals who were born in one week in 1958. Biological samples were collected from approximately 8000 study participants as part of a biomedical survey in 2002-2003. Additional blood samples from approximately 7000 study participants are being collected in the 2019-2021 biomedical sweep and will be added to the collection. The 1970 British Cohort Study (BCS) follows the lives of those born in one week in 1970. The 2016-2018 Biomedical Survey for BCS70 collected whole blood samples from approximately 6000 cohort members. The most recent of Britain’s renowned national longitudinal cohort studies, the Millenium Cohort Study (MCS), follows the lives of over 19,000 children in the UK born in 2000/1. At age 14 (MCS6) saliva was collected from approximately 9300 cohort members and 14,000 natural parents (where present in the home) to create a DNA bank. The subjects in these studies have been well characterised (phenotyped) for a variety of quantitative complex traits and been assessed for a variety of sociodemographic, socioeconomic and lifestyle variables. The resource is widely used for research in genetic and genomic epidemiology, in particular as a platform for genetic association studies. Data has been collected from the NCDS, BCS, Next Steps and MCS birth cohort participants via interviews, questionnaires and home visits since their birth in 1958, 1970, 1989/1990 and 2000/2001 respectively. The tissue bank however only holds a limited amount of information pertinent to managing the samples and the genotyping and analytical data generated from the samples. The tissue bank holds no identifying information, all samples and data held by the bank are linked by a participant id number. The resources in the tissue bank are available to bona fide research scientists. Access to samples will be subject to successful application to the CLS Data Access Committee. The majority of samples are stored at the University of Bristol. Milk teeth collected from Millennium Cohort Study participants are stored at the Eastman Dental Institute. | |
| CHHiP (Conventional or Hypofractionated High Dose IMRT for Prostate Cancer) | Surrey | CHHiP is a randomised phase 3, non-inferiority trial recruiting men with localised prostate cancer (pT1b-T3aN0M0). Patients were randomly assigned (1:1:1) to conventional (74 Gray (Gy) delivered in 37 fractions (f) over 7.4 weeks) or one of two hypofractionated schedules (60Gy/20f over 4 weeks or 57Gy/19f over 3.8 weeks) all delivered with intensity modulated techniques. The primary endpoint was time to biochemical/clinical failure; critical hazard ratio (HR) for non-inferiority was 1.208. The CHHiP trial is registered (ISRCTN97182923). From Oct 18, 2002 to June 17, 2011, 3216 men were recruited from 71 centres (74Gy: 1065, 60Gy: 1074, 57Gy: 1077). Median follow-up is 62.4 months (IQR 53.9-77.0). The proportion of patients biochemical/clinical failure-free at 5 years was 74Gy: 88.3% (95%CI 86.0-90.2), 60Gy: 90.6% (88.5-92.3), 57Gy: 85.9% (83.4-88.0). 60Gy was shown to be non-inferior to 74Gy: HR 0.84 (90%CI: 0.68-1.03) but non-inferiority could not be claimed for 57Gy: HR 1.20 (0.99-1.46). The α/β ratio for prostate cancer was estimated at 1.8Gy. There were similar long-term side-effects in all treatment groups with no significant difference in the proportion of patients reporting a RTOG grade 2 or worse bowel/bladder toxicity at 5 years (74Gy: 1.3%/1.7%, 60Gy: 2.3%/1.8%, p=0.26/p=1.00, 57Gy: 2.0%/1.8%, p=0.48/p=1.00). Hypofractionated radiotherapy using 60Gy/20f is non-inferior to conventional fractionation using 74Gy/37f and is recommended as a new standard of care. | |
| CHOIR | Greater London | The CHOIR biobank will support research into childhood onset ocular inflammatory disease: understanding how and why disease develops, and providing the information needed to help develop new treatments. The CHOIR biobank samples and data comprise: • Blood collected at time of any routine venesection • Tears obtained using filter paper strip (Schirmer strip) collection by eye doctor in clinic • Tissues considered excess from surgery on the eye including uveal tissue (iris samples) and intraocular fluid (aqueous) • Stool / faeces obtained by family at home or by family in clinic • Saliva obtained by family at home or by family in clinic and routinely collected clinical information. | |
| Clatterbridge Cancer Centre Biobank | Merseyside | The Clatterbridge Cancer Centre (CCC) has a well-defined mission to ‘improve health and wellbeing through compassionate, safe and effective cancer care’. Research for patient benefit is a fundamental part of CCC to conduct high quality research which translates into improved treatment and better prognosis for our patients. We established the CCC Biobank aims to provide high quality biological samples linked to patient outcome data to facilitate good quality research into the molecular mechanisms of cancer, biomarker discovery for early detection of cancer, patient stratification and into the reasons why some cohorts of patients fail to respond to therapeutic agents; all of which it is hoped will result in tangible patient benefit. The sample collection is entirely prospective following full informed consent from CCC patients diagnosed with cancer. The Biobank will also store samples donated from ‘healthy volunteers’ who have not been diagnosed with cancer in order to provide age matched controls. The samples will be used for the following cancer research procedures including, discovery and validation of: • Diagnostic biomarkers • Prognostic biomarkers • Predictive biomarkers • Biomarkers for emerging drug resistance • Biomarkers of toxicity • Molecular mechanisms of cancer The samples range across all cancer types and stage. | |
| Clinical Research Facility Respiratory Biobank, Royal Brompton and Harefield Hospitals | Greater London | Samples and data are available to researchers from hospitals, academia and commercial industry who are conducting research into lung disease. Samples include availability of fresh and stored tissue and blood from patients with respiratory diseases. | |
| COLO-PREVENT | Leicestershire | Clinical samples collected from participants in COLO-PREVENT, a world first trial platform in prevention that consists of a main phase 3 study comparing aspirin alone versus aspirin plus metformin, and a phase 2 signal seeking trial of resveratrol, conducted in high-risk patients recruited through the NHS Bowel Cancer Screening Programme. The phase 3 trial is a 3 year intervention with aspirin/metformin and the phase 2 trial is a 1 year intervention comparing low and high dose resveratrol against placebo. The following samples are being collected and are being stored and analysed as part of the COLO-PREVENT translational programme: 1) Plasma and serum collected at baseline, 6 monthly intervals and the end of the trial. 2) Fresh frozen and formalin fixed paraffin embedded biopsies of normal rectal tissue taken at the end of the trial. 3) FFPE diagnostic samples of colorectal polyps taken as part of the initial screening colonoscopy and any polyps removed during the surveillance colonoscopy at the end of the trial. 4) Faecal samples collected using a FIT kit, at baseline, 1 year (for the main trial) and study end. These will be completely used for microbiome analysis. 5) Urine samples from a proportion of patients in the phase 2 resveratrol signal seeking trial. | |
| COLO-PREVENT | Leicestershire | Clinical samples collected from participants in COLO-PREVENT, a world first trial platform in prevention that consists of a main phase 3 study comparing aspirin alone versus aspirin plus metformin, and a phase 2 signal seeking trial of resveratrol, conducted in high-risk patients recruited through the NHS Bowel Cancer Screening Programme. The phase 3 trial is a 3 year intervention with aspirin/metformin and the phase 2 trial is a 1 year intervention comparing low and high dose resveratrol against placebo. The following samples are being collected and are being stored and analysed as part of the COLO-PREVENT translational programme: 1) Plasma and serum collected at baseline, 6 monthly intervals and the end of the trial. 2) Fresh frozen and formalin fixed paraffin embedded biopsies of normal rectal tissue taken at the end of the trial. 3) FFPE diagnostic samples of colorectal polyps taken as part of the initial screening colonoscopy and any polyps removed during the surveillance colonoscopy at the end of the trial. 4) Faecal samples collected using a FIT kit, at baseline, 1 year (for the main trial) and study end. These will be completely used for microbiome analysis. 5) Urine samples from a proportion of patients in the phase 2 resveratrol signal seeking trial. | |
| CONCORDE Trial | West Yorkshire | CONCORDE is a clinical trial designed to assess recommended phase II dose for a number of DNA damage response inhibitors combined with radiotherapy for patients with non small cell lung cancer who are not suitable for concurrent chemoradiotherapy. As part of the trial blood samples will be collected and analysed as part of the exploratory endpoints at multiple laboratories. Once the trial exploratory analysis is concluded residual samples will be biobanked. | |
| Covid Symptom Study (CSS) Biobank | Greater London | Collection of plasma, DNA and fecal samples from Covid Symptom Study App participants with specific COVID symptomatology | |
| COVID-HEART | Leicestershire | The main aims of this study are, for a UK population, to characterise the prevalence and extent of myocardial involvement from COVID-19 infection, to assess recovery status at 6 months, and to understand the impact on patient quality of life and functional capacity. As part of the COVID-HEART protocol, there is a blood biomarker and genetic sub-study which participants will have the option of participating in alongside the main study. | |
| DARWIN1 Trial | Greater London | Blood and tissue from lung cancer patients | |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II) | Greater London | A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis | |
| Demyelinating Research Tissue bank | Oxfordshire | Tissue for the study of demyelinating conditions: clinical, genetic and immunological studies. | |
| Dental, Oral and Craniofacial Biobank | Greater London | The Dental, Oral and Craniofacial Biobank is managed by King's College London and is a repository of samples from patients from dental clinics at Guy's and St-Thomas Foundation Trust and within the wider King's Health Partners trusts. Samples collected include salivary, microbial, gingival crevicular fluid (GCF) samples, buccal swabs, blood samples, hard and soft oral tissues, tears and stool samples from patients attending new patient/consultant clinics. The biobank also collects demographic, clinical and quality of life (OHIP-14) data. | |
| DETECTION | Greater Manchester | TBC | |
| DETERMINE | Greater London | DETERMINE (Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly defined Indications using a National Evaluation platform trial) An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations, including Common Cancers with Rare Actionable Alterations | |
| Digestive diseases bioresource | Greater London | Adult and paediatric GI and liver diseases (including surgery), Barts Health NHS trust Only available as formal collaborations with the internal team. No specimens / data sent to external organisations outwith collaborations. | |
| DOC-MEK | Oxfordshire | A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. The aim of this study was to assess the efficacy and safety of selumetinib combined with docetaxel as first-line treatment in patients with wild-type BRAF advanced melanoma. | |
| Donate For Research Initiative (DRI) | Cardiff | Focusing on the procurement and supply of Fresh Biological Human samples and prospective studies. Open collaborations with other research Tissue Banks to facilitate multidisciplinary research and coordinated collections to benefit life science researchers. | |
| Early Pregnancy Tissue Collection | Greater Manchester | Embryonic and fetal tissue (including placenta) collected from voluntary terminations of pregnancy | |
| eLIXIR - Early Life Data Cross-Linkage in Research | Greater London | The embryo, fetus and newborn child are very sensitive to external influences during development. These can arise from problems with the mother's health, her lifestyle, her physical environment, medication, the placenta not working properly, complications during birth, or as consequence of being born too early. Adversity in these periods of developmental vulnerability can have persistent effects on the long-term health of the child, including physical and mental health disorders. We also know that if a mother has complications in pregnancy, that she herself may suffer from increased risk of ill-heath in later life, for example cardiovascular disease, diabetes or mental health problems. eLIXIR is a prospective collection of blood samples from routine antenatal and neontal appointments which began collecting samples in October 2018. Collection continued during COVID and is still ongoing. | |
| EMR Arthritis Biobank | Greater London | The EMR Arthritis Biobank provides a unique bio and data resource, with biological samples (tissue and fluids) and stringent clinical data collected from patients recruited to our various clinical trials/studies including PEAC, R4-RA, STRAP/STRAP-EU, Therapist, IRMA, PSABRE, BHSLE & TRACTISS (completed and on-going studies). Patients recruited to our studies have rheumatic conditions such as Rheumatoid, Psoriatic and Undifferentiated Arthritis, as well as auto-immune diseases such as Lupus and Sjogren's syndrome. | |
| EPHOS-B Trial | Surrey | Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study – Biological Phase (EPHOS-B). The EPHOS-B trial is a multicentre, three group, randomised controlled trial conducted in two parts. Part 1 (protocol versions 1 to 4): HER2+ patients were allocated in a 1:2:2 ratio to control, perioperative trastuzumab only or perioperative lapatinib only. This part of the trial will be superseded by Part 2 following the approval of amendment 5 by West Midlands - Edgbaston NRES Committee on 15/05/2013 and subsequently in each centre. Part 2 (Implemented from protocol version 5): HER2+ patients are allocated in a 1:1:2 ratio to control, perioperative trastuzumab only or the combination of lapatinib and trastuzumab. This part is now active. | |
| Epilepsy Society Brain and Tissue Bank | Greater London | The Epilepsy Society Brain and Tissue Bank is a recently established tissue bank at the Institute of Neurology, which has ethical approval and is supported by the Epilepsy Society. It is located within UCL Institute of Neurology in the Department of Neuropathology and is governed by a committee including members of the Department of Clinical and Experimental Epilepsy, the Epilepsy Society as well as SUDEP Action. The collection comprises consented tissue samples from patients who have undergone epilepsy surgery, mainly at the National Hospital for Neurology and Neurosurgery. In addition the tissue bank archives whole brain samples from patients with epilepsy and particularly epilepsy-related deaths, such as sudden and unexpected death in epilepsy (SUDEP). We have a donor registry for people who have epilepsy, seizures or who are healthy, without seizures, who wish to donate brain tissue following death. | |
| ESPAC-TPlus | Lancashire | To centralise tissue and other clinical samples from the ESPAC studies, and make them available for future studies. Storage of the samples is designed to facilitate specific studies on response to chemotherapeutics. These separate studies will be subject to individual ethics applications. If successful they will allow subgroups of patients to be identified who will be predicted to benefit from particular chemotherapeutic regimens, improving survival for individual patients and facilitating clinical trials. | |
| Ethical Tissue - University of Bradford | West Yorkshire | Ethical Tissue is a research tissue bank, licensed by the Human Tissue Authority (HTA); to collect, store and supply a wide range of human tissue, cells and fluids to biomedical research groups in academia and industry. Also includes tissue donated after death. | |
| EXCEED study | Leicestershire | EXCEED is a longitudinal population-based cohort which facilitates investigation of genetic, environmental and lifestyle-related determinants of a broad range of diseases and of multiple morbidity through data collected at baseline and via electronic healthcare record linkage. * Recruitment has taken place in Leicester, Leicestershire and Rutland since 2013 and is ongoing, with approximately 10,000 participants aged 30-69 to date. The population of Leicester is diverse and additional recruitment from the local South Asian community is ongoing. * Participants have consented to follow-up for up to 25 years through electronic health records and additional bespoke data collection is planned. * Data available includes baseline demographics, anthropometry, spirometry and lifestyle factors (smoking and alcohol use), and longitudinal health information from primary care records, with additional linkage to other EHR datasets planned. Patients have consented to be contacted for recall-by-genotype and recall-by-phenotype sub-studies, providing an important resource for precision medicine research. * We welcome requests for collaboration and data access by contacting the study management team via exceed@le.ac.uk. | |
| Extracted teeth Biobank | Cheshire | Samples and data are donated on the basis that they will be used for the benefit of other patients and for society in general. The bank plans to maximise benefits to society by using the extracted teeth to develop improved methods of detecting tooth decay. The caries detection rate of different methods can then be compared with the "ground truth". which uses an histological examination of the teeth. We propose to publicise the existence of the bank on | |
| FiTNEss (Myeloma XIV) | West Yorkshire | Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I). | |
| Generation Scotland | Midlothian | A collaboration between the Universities of Edinburgh, Glasgow, Dundee and Aberdeen, and NHS Scotland, to provide resources for genetic and medical research. | |
| Genome Damage and Stability Centre-Research Tissue Bank | East Sussex | The Genome Damage and Stability Centre’s (GDSC) Cell bank was established in 1975. It houses material (skin biopsies, fibroblast and lymphoblastoid cell lines) collected from individuals, with various genomic instability disorders, with the aim of understanding more about the molecular basis underlying these disorders and providing data which aids the diagnosis and treatment of affected patients. | |
| Glasgow Caledonian University | Glasgow (City of) | The GCU Skin Research Tissue Bank provides annotated normal and diabetic skin tissue samples to support research into human skin disease. We operate closely with the NHSGGC Biorepository alongside our NHS Consultants. All acquisition of tissue complies with Governance approved by the Biorepository who have oversight in supporting tissue collection and anonymisation of samples. Our ethical oversight and approval (21/WS/0088) is currently valid until July 2026. The GCU Skin Tissue Bank holds fixed and frozen tissue along with fibroblasts and keratinocytes derived from donor samples. | |
| Glasgow Traumatic Brain Injury Archive | South Lanarkshire | The Glasgow TBI Archive is comprised of materials from TBI patients across a range of ages from infants to elderly. This unique archive includes material from: - Over 2000 case of single or repetitive TBI as paraffin wax blocks sampled from immersion fixed whole brain specimens - Approximately 50 TBI cases as snap-frozen fresh tissue samples - An extensive archive of uninjured control tissue samples as paraffin tissue blocks and snap-frozen tissue - Over 1200 DNA samples from patients in ongoing clinical studies in TBI Each case has been meticulously gathered using standardised sampling protocols. All specimens are linked to fully anonymised demographic data and relevant clinical information – which includes details on injury, cause of death , postmortem interval and neuropathological findings. The causes of TBI include, but are not limited to, falls, road traffic accidents, assaults and sports-associated TBI. The influence of the Glasgow TBI archive can be traced through the literature on the neuropathology of human TBI, with in excess of 150 peer-reviewed publications derived from observations on material from this resource. This includes landmark and continued observations on axonal injury and neurodegeneration after TBI. | |
| GlaxoSmithKline Research Tissue Bank | Hertfordshire | GlaxoSmithKline R&D has a global biobank network storing human biological samples from GSK R&D sponsored clinical trials, collaborations and commercially procured samples. These samples span the following main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, Respiratory, Inflammation and AutoImmunity. There are several million samples logged in the GlaxoSmithKline R&D sample tracking systems. Work needs to be done to identify which specific sample sets can be shared (both from closed clinical trials and from those that were commercially acquired), by establishing those that have the appropriate consent level and data available and to get the necessary approvals in place for access these samples. | |
| GoDARTS | Angus | The GoDARTS Study has stored specimens of whole blood, serum, urine and DNA from consented patients with type 2 diabetes and matching controls (non diabetics) resident in the Tayside region of Scotland. Additionally GWAS data on ~10,000 cases is available. This resource is available to researchers worldwide to help define genetic factors related to diabetes including susceptibility, complications and response to treatment. | |
| GOLF: Generation of a Lung Biobank for Future Use | Surrey | GOLF: Generation of a Lung Biobank for Future Use | |
| Great Ormond Street Hospital Sample Bank | Greater London | The GOSH Sample Bank initiative was launched in 2019, enabling patients to donate their leftover samples to be used for vital child health research instead of them being discarded. The samples (including urine, blood, faeces or biopsies of skin and other tissue) will allow us to carry out more research to better understand rare and complex conditions and develop new treatments. We aim to build a rich resource of samples without the need to ask for extra tests or donations from our patients. | |
| HaemBio Biobank | Oxfordshire | Biobanking Biological Samples for Research in Haematological Malignancies | |
| HALT | Surrey | HALT is a phase II/III, multicentre, randomised controlled trial in patients with advanced non-small cell lung cancer (NSCLC). Patients will have a defined, actionable mutation responding to targeted tyrosine kinase inhibitor (TKI) therapy and 3 or fewer sites of oligoprogressive disease, which will have developed after becoming resistant to targeted TKI treatment. 110 patients will be randomised to phase II of HALT with participants allocated to receive Stereotactic Body Radiotherapy (SBRT;73 patients) or not (37 patients). All patients will continue TKI therapy. The phase II study aims to evaluate if the addition of SBRT to treat limited (≤ 3) sites of oligoprogressive disease with continuation of current TKI therapy improves progression-free survival outcomes in patients compared with continuation of TKI alone. The focus of the translational research will be on identifying clinically translatable biomarkers to identify patients who are likely to benefit from SBRT versus patients where transition to the next line of systemic therapy would be appropriate. | |
| HCV Research UK | Glasgow (City of) | HCV Research UK is a UK-wide consortium established in 2011 to underpin research into hepatitis C (HCV). This was achieved by establishing a biorepository and clinical research database. The biorepository is housed in the MRC-University of Glasgow Centre for Virus Research, directed by Dr John McLauchlan and managed by Dr Sarah McDonald. Samples have been obtained from around 10,000 patients. Access to samples and data is governed by a Tissue and Data Access Committee (TDAC). These are reviewed for ethical and scientific merit by TDAC and a decision reached. Serum and plasma are obtained from all patients in the cohort. Buffy coats are also collected, and DNA can be extracted when required. Additionally, peripheral blood mononuclear cells (PBMCs) and PAXgene tubes are held for smaller cohorts of patients. The extensive clinical data collected complements the biorepository and allows selection of samples from patients with characteristics of interest. Sub-cohorts: • Serial samples from patients who were treated as part of the NHS England Early Access Program. • Yearly samples from cirrhotic patients (beginning 2015) • Spontaneous resolvers • Small paediatric cohort Clinical Data • Basic demographics incl place of birth and ethnicity • History of HCV infection including exposure to risk factors and dates • Date of diagnosis, date of first attendance at clinic • Co-morbidites and co-medications at time of enrolment • Liver disease status and how diagnosed • Treatment status at enrolment; • Social history including alcohol, cigarettes, cannabis; BMI • HCV RNA status, viral load and genotype/subtype • Historical data from the patients' notes regarding previous treatment episodes (dates, regimen, viral loads, outcome) and liver biopsies • Laboratory data including imaging and fibroscan; • New treatment episodes and changes in liver disease status are recorded over time, as are any newly developed co-morbidities. All data generated by researchers who access our biorepository must be returned into the database. Over time this will include host genetics, full length viral sequences, immunophenotyping and biomarker studies. | |
| HPB Biobank | Greater London | Prospectively collected fresh tissues from surgery. All patients fully consented. Snap frozen paired cancers and normal tissues. Stored in liquid nitrogen HCC Cholangiocarcinoma Liver mets Benign tumours Gallbladder cancer Pancreas and ampullary cancers 1010 samples currently in bank | |
| Human Biomaterials Resource Centre | Warwickshire | The HBRC is an HTA-licensed biorepository dedicated to the collection of appropriately consented high quality human biomaterials, their processing, storage and distribution to biomedical researchers. The HBRC resides within the purpose-built Advanced Therapies Facility (ATF) within the College of Medical and Dental Sciences (CMDS) at the University of Birmingham (UoB). The ATF also houses both cell and gene therapy manufacturing units. Samples are collected, processed and stored (or released) from patients in a variety of disease settings in response to local demand and research strategies in order to facilitate existing research and enable future research areas to be developed. Samples may comprise adult or paediatric tissue which is waste, or surplus to diagnosis taken at the time of surgery or treatment, additional samples taken specifically for research purposes, material taken from patients enrolled in clinical trials, and control material. The HBRC works with local researchers and carries out bespoke tissue collections. All samples can be annotated with the appropriate clinical data which makes them scientifically useful. Although the HBRC is primarily a resource for local researchers within CMDS and local NHS Trusts, applications from other UK research groups and the commercial sector are also considered. The policy and procedures associated with the review of these applications, and the subsequent release of samples and associated data, are the same for both internal and external applicants. All samples and associated data are released for research in a fully anonymised form, and a Tissue Transfer Agreement ensures that they will only be used for the purposes approved at release and will not be transferred without written permission. In order to enhance the value of the HBRC collection, every attempt is made to secure the return of useful research data following the completion of research studies. | |
| Human Developmental Biology Resource (HDBR) | Northumberland | The Human Developmental Biology Resource (HDBR) is an ongoing collection of human embryonic and fetal material ranging from 3 to 20 weeks of development. Material is available to researchers internationally following registration with the tissue bank. Jointly funded by the MRC and Wellcome Trust, the biobank has been operating since 1999 and is based at two centres: Institute of Genetic Medicine – Newcastle University and the Institute of Child Health – University College London. Tissues can be dissected to meet specific research needs and samples supplied fixed or frozen for histology or nucleic acid extraction, or the tissue can be collected into culture media to be used to establish cell lines. Material pre-sectioned to microscope slides is available for immunohistochemistry (IHC) or tissue in situ hybridisation studies (TISH) and stage, tissue specific RNA/DNA/cDNA can be requested. Our In House Gene Expression Service will perform IHC or TISH experiments on behalf of registered users and provide them with high quality annotated images of results ready for publication. | |
| Human Post-Mortem Fetal and Neonatal Brain Tissue Resource | Greater London | The Human Post-Mortem Fetal and Neonatal Brain Tissue resource has fixed (formalin-fixed paraffin-embedded tissue) and a limited range of fresh frozen brain samples from fetal and neonatal ages (20 – 44 weeks gestation). There is also associated (and anonymised) clinical history for each sample. This resource, and requests for tissue are accessible to the national and international scientific community conducting both basic and translational medical research. Aim: Disturbances to brain development in fetal life predispose and contribute to the aetiology of numerous neurodevelopmental disorders. The use of these tissues aims to help researchers understand the underlying neurobiology of typical and atypical brain development. | |
| Human primary fibroblasts | Essex | Human primary fibroblasts derived from human tunica albuginea, skin and lung | |
| Human Research Tissue Bank Cambridge | Cambridgeshire | The Human Research Tissue Bank is based at Cambridge University Hospitals - Addenbrooke's Hospital, within Pathology and stores human frozen and FFPE tissue for research purposes. We also offer a range of histological services. | |
| hVIVO Services Ltd. | Greater London | At hLAB (part of hVIVO) we provide a research biobank with human biospecimens for research from a UK-based specialist contract research organisation and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. Through our research biobank service, where we are committed to advancing healthcare through collaborative efforts in key clinical areas. With a focus on vaccine development, immunology, oncology, and respiratory research, our biobank serves as a vital resource for researchers across the UK. | |
| ICON9 Trial | Greater London | An international phase III randomised study to evaluate the efficacy of maintenance cediranib and olaparib combination therapy or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy | |
| IDRIS Trial | Greater London | Phase III randomised study of immunomodulatory therapy in high risk solitary bone plasmacytoma. IDRIS is a randomised, open label, multicentre phase III study. The aim is to investigate whether the administration of adjuvant lenalidomide and dexamethasone following standard radiotherapy treatment for SBP prevents or prolongs the time to development of further plasmacytomas or progression to myeloma, or death (whichever comes first), in patients with high-risk disease compared with RT only. Patients are risk-stratified following registration into the trial. Risk stratification is based on BM immunophenotyping and SFLC ratio. All patients will receive standard local radiotherapy; this is not regarded as trial treatment and may be administered prior to study entry. - Patients with high-risk features will be randomised to receive adjuvant therapy in the form of lenalidomide and dexamethasone or no further treatment. - Patients without high-risk features will receive no further therapy and will be observed according to local practice. 140 patients: - 98 patients with high risk features to be randomised at a 1:1 ratio - 42 low risk patients for registration only | |
| Imperial College Healthcare Tissue Bank - ICHTB | Greater London | Human tissue bank holding samples in a variety of different formats at Imperial College London | |
| Imperial College London | Greater London | The Communicable Diseases Research Tissue Bank was established to provide research materials for a range of infections but with a focus on human retroviruses, other blood-borne viruses and sexually transmitted pathogens | |
| Imperial Hepatology & Gastroenterology Biobank | Greater London | The Imperial Hepatology and Gastroenterology Biobank (IHGB) was set up in September 2010 and received original Research Tissue Bank (RTB) approval from South Central Oxford C Research Ethics Committee C in 2011. Subsequent applications for the IHGB RTB to continue were approved by South Central Oxford C Research Ethics Committee C in January 2016 (16/SC/0021), and again by the same Research Ethics Committee (20/SC/0389) in 2020/2021. The Imperial College London Division of Hepatology and Gastroenterology carries out research into a wide range of diseases. The Division is closely aligned with the clinical Hepatology and Gastroenterology services of Imperial College Healthcare NHS Trust The Imperial Hepatology & Gastroenterology Biobank (IHGB) was established to maximise the scientific benefit of samples accrued in existing clinical research studies, and to permit prospective sample collection from the unique cohort of patients treated by the clinical service each year, and so the Biobank forms a repository for samples remaining at the end of current studies, as well as for samples donated directly by patients and healthy volunteers. The Biobank Governance Committee (BGC) ensures that such samples are collected, archived, and used within an ethical framework. This Biobank’s primary purpose is to facilitate high quality research within Imperial College, but applications from external groups to use specimens and data are also considered. | |
| IMPORT HIGH trial blood samples | Surrey | Blood samples from patients with early stage breast cancer who received breast conserving surgery and appropriate systemic therapy and radiotherapy. | |
| INCA Trial | Greater London | INCA is a multicentre, randomised, phase II trial comparing IO-R-CVP with Gem-R-CVP in the first line treatment of patients with DLBCL who are not fit for anthracycline-containing chemotherapy. 132 patients will be randomised to receive either IO-R-CVP or Gem-R-CVP. Samples collected for trial: 7ml EDTA blood sample taken at baseline; Formalin fixed paraffin embedded tumour block - both sent to HMDS, Leeds. Blood serum sample (4.9ml) taken at Baseline (between day -14 pre registration and day 1 pre-treatment), Cycle 1 day 3 (+/- 1 day), Cycle 1 day 8 (+/-1 day) and Cycle 2 day 1 (-1 day) to be sent to Cancer Research UK Manchester Institute, Macclesfield. | |
| Infection and Immunity Biobank | Greater London | The Biobank’s aims include to: • Facilitate research by obtaining and storing donor samples which can be used for future ethically approved research • Enhance the availability of SGUL samples to researchers. The aim is to support primarily research in the I&I, but it will also support SGUL partners, as well as researchers nationally and internationally | |
| Infectious Diseases BioBank at King's College London | Greater London | Fractionated blood products from patients with HIV and bacteraemias | |
| Inflammatory Liver Diseases Biobank | Devon | The collection aims to provide a resource for investigation of inflammatory liver diseases and includes serum, plasma, DNA, PBMCs and urine samples from donors with a range of inflammatory liver diseases. Where relevant, donors to the biobank may also have consented to collection of stored or fresh liver tissue samples from liver resections for primary hepatocellular carcinoma, cholagio carcinoma or colorectal liver metastases. | |
| Inherited Aortic & Related Connective Tissue Disorders Biobank, v1 | Kent | In the early 1990s, we set up long-term collaborative studies whereby patients and their families with different types of connective tissue disorders were ascertained, and with informed consent, gave blood samples to help our international research team discover the underlying cause of their connective tissue disorder. For this purpose, tissue, blood and/or DNA samples were kept frozen, and resulting in the creation of the Inherited Aortic & Related Connective Tissue Disorders Biobank. Recently, a new interest in using modern DNA analysis techniques to help review these families, has arisen. This necessitates further exchange of samples, from the biobank, to Dr Aragon-Martin (Research Director of Sonalee Laboratory and Manager of the Inherited Aortic & Related Connective Tissue Disorders Biobank) who will further these studies in the Sonalee Laboratory. These samples were initially collected by Dr Anne Child, with funding from the Marfan Trust. Now, this collection is going to become a biobank that is the compilation of many connective tissue disorders and samples through many years of studies, creating a priceless collection for research. | |
| Integrated Clinically-Augmented Repository for Universal Sampling | Cambridgeshire | Neuro oncology biobank at the University of Cambridge | |
| interNational Anaplastic Thyroid Cancer Tissue Bank (iNATT) | Cardiff | The primary objective is to establish an international anaplastic thyroid cancer tissue collection to facilitate research. Patients have the option to donate blood samples and clinical data. Research proposals will be accepted from academic and industry research parties from the UK and internationally. All research proposals will be submitted to the multidisciplinary iNATT Steering Committee for assessment. As the volume of tissue collected per patient is expected to be of small volume, by virtue of the specimen comprising core biopsy or fine needle aspirate material, research proposals will be prioritised according to the potential clinical benefits. Research proposals will require ethical approval and the relevant research and development permissions prior to commencement. ClinicalTrials.gov Identifier: NCT01774279 | |
| IoN Trial | Greater London | IoN is a multicentre phase II/III asking is ablative radioiodine necessary for low risk differentiated thyroid cancer patients. 560 patients will be recruited and randomised 1:1 to receive radioiodine ablation or no ablation. Samples collected during trial: Stimulated Tg blood samples for patients taken at the treatment visit, 2 months post treatment, 6-9 months post treatment and every 6 months thereafter for 5 years. | |
| KCL Centre for Medical Engineering Imaging Bioresource | Greater London | The Centre for Medical Engineering Imaging Bioresource will provide a resource of clinical data, clinical images (e.g. MRI/PET scans) and biological samples (blood, saliva, formalin-fixed paraffin-embedded tissue) to be used in medical research with the following research focus: · Improving long-term neurological outcomes of sick infants and children and developing biomarkers to stratify and optimise treatment in neuropsychiatric disease. · Improving outcomes of patients with chronic cardiac conditions, particularly structural and ischaemic heart disease, heart failure and cardiac arrhythmias. · Improving the care of patients with cancer with better stratification and improved treatment selection, as well as identifying ineffective treatments early so they can be changed. The Centre for Medical Engineering Imaging focuses on the science and engineering of medical imaging. Scientific and technological breakthroughs in this area have changed our understanding of disease and clinical practice, and have significant potential for further transformative impact. Our ultimate aim is to improve the care and outcomes of patients with neurological, cardiovascular and oncological conditions. We aim to deliver this by providing the infrastructure needed to deliver strong, grant-funded research through building a unique Imaging Bioresource with novel ways of extracting and presenting information. We wish to maximise the use of the data we produce by creating an Imaging Bioresource for the collection of images along with clinical information and biological specimens (e.g. blood, saliva, tissue) for analyses. Applications with research questions in the remit of the Centre for Medical Engineering Imaging will be considered for approval: “To improve outcomes for patients with neurological, cardiovascular and oncological conditions using our underpinning research themes of physics and engineering, computer science, imaging chemistry and interventional engineering.” For further information please contact: imaging-bioresource@kcl.ac.uk | |
| KCL Human Islet Research Tissue Bank | Greater London | Human pancreatic islets will be isolated from deceased donors at King's College Hospital (KCH). Islets which are not suitable for transplantation purposes, will be transported to King's College London (Department of Diabetes, Guy's Campus) for research use either fresh or frozen and stored. | |
| Kidney Transplant Biobank | Greater London | Prospective longitudinal sampling of serum, PBMCs, urine and faecal samples from live-donor patients and recipients of live-donor and cadaveric renal transplants. | |
| King's Adult Liver Research Biobank | Greater London | Biobank storing a collection of blood and blood fractions, tissue (fixed and frozen) and a variety of other tissue types from a variety of conditions of the Liver and Hepatobiliary tract, including the pancreas. | |
| King's College London Motor Neurone Diseases Biobank | Greater London | The aim of the KCL MND Biobank is to collect samples and data from people with Motor Neurone Disease (MND) and those without the condition to understand the genetics behind the development of MND. Patients with Motor Neurone Disease (MND) and healthy volunteers over the age of 16 years of age will be eligible to participate in this biobank, provide a blood or saliva sample and demographic data. Researchers wishing to access the data and samples from this resource can do so once they have completed the access application form and this has been reviewed and approved by our access committee. A material transfer agreement is also required between King’s College London and the requesting institution prior to receiving any data or samples. | |
| King's Health Partners Cancer Biobank | Surrey | King's Health Partners Cancer Biobank collects blood, tissue and urine samples from patients with a range of cancer types who are referred to Guy's & St Thomas' NHS Trust. The Breast Biobank alone has been providing tumour samples with matching clinico-pathological data for research studies since the 1970's. Other tumour types including lung, head and neck, prostate, UGI, bladder, colorectal, lymphoma and MPD have been added since 2008. The Biobank is accessible to both academic groups and commercial companies. | |
| King's Paediatric Liver Tissue Biobank | Greater London | The paediatric liver tissue bank contains samples from children with rare liver diseases taken longitudinally. | |
| kings college Haemato -Oncology Tissue bank | Greater London | The objective of our Tissue Bank is to serve as an international bioresource to facilitate basic and translational research into the aetiology, diagnosis and prognosis of blood cancers and to pursue this aim in a manner that complies with all laws, regulations and industry standards that apply to research tissue banking.Thus, our bank is rich in material from adult patients with pre-leukaemic and bone marrow failure disorders, including myelodysplastic syndromes, aplastic anaemias and paroxysmal nocturnal haemoglobinurea. The bank is also populated with material from patients with chronic and acute myeloid leukaemia, myeloma and chronic lymphocytic leukaemia. | |
| LBIH Biobank | Lancashire | The LBIH Biobank has been specifically created to provide SMEs and academic researchers with high quality biosamples, data, and analytical services. We house a vast array of biosamples, both cancerous and non-cancerous, and have the ability to collect bespoke samples and data to suit the needs of researchers. We have access to a wide variety of samples types including, but not limited to, frozen tissue, fresh tissue, blood products, urine and FFPE blocks. The LBIH Biobank can further process these into a number of products such as DNA, frozen sections, and cryo-aliquots. In order to offer a ‘one-stop shop’ for research, we offer additional services such as IHC, next generation sequencing,TMA creation, and project management for studies and projects, to include storage of trial samples. | |
| LCTC Post-Trial Tissue Bank | Merseyside | The collection consists of samples and data collected from individuals who have participated in clinical trials managed by the Liverpool Clinical Trials Centre and who have given informed consent for the use of their samples in translational research activity. The samples and data available fall under five core malignancy groups: •Hepato-pancreato-biliary (HPB) cancers •Uveal melanoma •Head and neck cancers •Breast cancer •Lung cancer Samples stored in the collection include, but are not limited to whole blood, cell pellets, tissue (tumour and healthy), plasma, peripheral blood mononuclear cells and urine. Samples will become part of the LCTC Post-Trial Tissue Bank upon completion of the intended primary translational objectives. Linked, anonymised data includes demographic, clinical and fully audit tracked laboratory data. | |
| Leeds Dental Institute/School of Dentistry Leeds, Skeletal Tissues Bank | West Yorkshire | Tissue bank which stores teeth. | |
| Leeds Multidisciplinary Research Tissue Bank | West Yorkshire | Background: The Leeds Biobanking and Sample Processing Lab (LBSPL) is based at St James’s University Hospital and is an important element in the Leeds Clinical Research Facility (LCRF). LBSPL is dedicated to providing a sample processing service for clinical trials, and for many biobanking activities within the University and Leeds Teaching Hospitals Trust. These currently include collections of tissue, and fluid samples such as blood and urine obtained from consented patients diagnosed with kidney, bladder, colorectal and ovarian cancer, brain tumours, and patients undergoing renal transplant. These are processed and stored in research tissue banks (Leeds Multidisciplinary RTB and Leeds NIHR Biomarker RTB) and used as a valuable resource for wider research activities. The Leeds Multidisciplinary Research Tissue Bank (RTB) was given favourable ethical opinion by the Leeds (East) Research Ethics Committee on 3rd March 2010 and renewed 5 yeasr later (Current REC ref: 15/YH/0080). Current situation: The LBSPL provides ongoing sample processing support to a variety of local or commercial clinical trials requiring samples to be collected for PK/PD endpoints or other associated translational studies. The Leeds Multidisciplinary RTB currently holds matched normal and malignant frozen renal tissue samples from ~600 patients with renal cancer, and plasma, serum, buffy coat and urine samples from ~800 renal cancer patients either prior to surgery/treatment or during treatment, for example with sunitinib. In addition, fluid samples have been collected from patients with benign urological conditions, healthy controls, patients prior to and following renal transplant A population-based TMA including tissue from ~300 RCC patients has also been established.From having solely a renal focus, the RTB has expanded to now also include frozen normal tissue samples, and frozen tissue and urine samples from >1,000 patients with bladder cancer, frozen tissue from patients with brain tumours and limited samples from patients with ovarian cancer or colorectal cancer (no new collections ongoing in these areas). The Leeds NIHR BioRTB has closed to recruitment and contains a bank of fluid samples from patients with liver disease, renal cancer and patient undergoing renal transplantation. These were collected as part of a multicentre initiative in the UK, together with associated clinical data, and are intended for use in biomarker validation studies. Sample processing and clinical data: Samples are processed according to the relevant quality controlled Standard Operating Procedures (SOPs) within Good Clinical Practice (GCLP) laboratories. The dedicated sample processing team of laboratory technicians, administrative staff and a Quality Assurance manager works together to ensure that all samples are handled, processed, stored and tracked to the highest standards. The samples are stored accordingly at the correct temperature (e.g. snap frozen tissue in liquid nitrogen, plasma, serum and buffy coats at -80oC). All freezers and liquid nitrogen dewars which hold patient samples are monitored using the Tutela system, a 24/7 web-based alert response temperature monitoring system. Full clinical data is being collected using CRFs. Follow-up data and data available later such as pathology results are obtained from the relevant hospital records/databases by trained personnel with appropriate access. We hope to move to more automated data linkage in the future through working with the Leeds Institute of Data Analytics. To find further information about collaborative access to these RTB samples please e-mail Roz Banks or Jo Brown at rtb@leeds.ac.uk. | |
| Leeds Neuropathology Research Tissue Bank | West Yorkshire | A repository of brain and blood samples from patients with neuropathologies (brain tumours and epilepsy). The Leeds Neuro RTB is jointly funded by OSCAR's Paediatric Brain Tumour Charity and Yorkshire Brain Tumour Charity. | |
| Leeds NIHR Biomarker Research Tissue Bank | West Yorkshire | Background: The Leeds NIHR Biomarker Research Tissue Bank (RTB) is part of a National Institute for Health Research (NIHR) Programme Grants for Applied Research award, focused on biomarker evaluation in selected disease areas. The RTB was established for the multicentre collection and storage of samples from patients with liver diseases recruited within a randomised controlled trial (ELUCIDATE) of a biomarker panel, renal cancer patients and patients undergoing kidney transplant. The Leeds NIHR Biomarker RTB is jointly managed along with the Multidisciplinary RTB by the Joint RTB Management Committee. The Leeds NIHR Research Tissue Bank (RTB) was given favourable ethical opinion by the Leeds (East) Research Ethics Committee on 15th June 2010 (Current REC ref: 15/YH/0099). Sample collections: Over the duration of the programme, 2,116 participants were recruited in total with 5,976 samples. Sample collection has taken place in multiple centres in the UK. These comprise: • 847 patients with liver disease each with a single serum samples • 514 patients on the kidney transplant waiting list including 312 subsequently transplanted, with 3,806 samples, each sample including multiple aliquots of serum, plasma and urine • 706 patients with suspected renal cancer (200 longitudinal and 506 cross-sectional) with 1,132 samples, including multiple aliquots of serum, plasma, buffy coat and urine and an FFPE tissue block (frozen available in Leeds patients only) • 149 healthy volunteers with 191 samples, each sample including multiple aliquots of serum, plasma and urine All samples were collected according to SOPs and have been shipped from the participating sites and stored centrally in Leeds Biobanking and Sample Processing Facility. Associated clinical data has been collected using standard study-specific case report forms (CRFs), including long-term follow-up in many cases. Initially access to samples is prioritised for the needs of the Programme and investigators involved but additional collaborative access will then be possible. To find out further information please e-mail our Research Tissue Bank and Sample Processing Facility Manager, Pirkko-Liisa Muhonen at rtb@leeds.ac.uk. | |
| LEGACY blood | Cambridgeshire | ‘LEGACY blood’ is a research study aiming to understand what effects health, lifestyle and ageing have on acquired DNA changes in blood cells (clonal haematopoiesis) and on the immune system. | |
| Leicester Institute for Lung Health Research Tissue Bank | Leicestershire | Medical research is currently in an era in which thousands of genes, RNA molecules and proteins can be analysed in a single experiment, meaning that large numbers of potential molecular markers for disease are being identified. To validate and translate these biomarkers large series of tissue and other biosamples are required. The Leicester Institute for Lung Health (LILH) Research Tissue Bank (RTB) is intended to meet this need and to facilitate high quality research. The LILH RTB will support projects from all sections of the respiratory research community within Leicester, while remaining open to provision of tissues and samples to organisations outside Leicester. Researchers from academic, charitable and commercial organisations will be able to apply for access to banked tissue samples. | |
| Liverpool Musculoskeletal Biobank | Merseyside | The Biobank aims to facilitate musculoskeletal research. To support primarily research in the University of Liverpool. It will also support other research partners both nationally and internationally. A variety of musculoskeletal tissues are collected prospectively from consented patients undergoing both elective and trauma orthopaedic surgery. Patients demographic and medical history is obtained as well as outcome and quality of life assessment scores. We are able to collect all orthopaedic surgery waste products e.g. cartilage, bone, synovium, synovial fluid, adipose tissue, ligaments, muscle, capsule, bone marrow and venous blood samples. | |
| Liverpool Neuroscience Biobank at the Walton centre (LNBW) | Merseyside | Liverpool Neuroscience Biobank at the Walton centre (LNBW) has been established to promote multidisciplinary basic and translational neuro-oncology and neurology research. It includes archived and prospectively collected samples from patients who are investigated at The Walton Centre. We have merged two previously established biobanks, the Walton Research Tissue Bank (WRTB) -Ref: REC 15/WA/0385 and Walton CSF Research Biobank (WCRB)- Ref: REC 16/WA/0291 into one as LNBW to enhance the scope of governance, research and collaborations to facilitate multicentre research. LNBW has received full approval of the Wales REC4 National Research Ethics Service [REC ref 20/WA/0043] until 2025 and is held under a Human Tissue Authority Licence at The Walton Centre NHS Foundation Trust. The operation of the LNBW is overseen by a management committee, whose role is to ensure that samples are used appropriately in relevant research projects and is fully supported by Trust Management; facilitated by clinical and neuroscience laboratories staff. All patients undergoing a clinical procedure at The Walton centre are invited to participate and donate samples to LNBW for research. Patients are recruited with appropriate research consent forms (along with patient information sheets) and relevant samples like fresh tissues and cerebral spinal fluid (CSF) are matched with bloods and are collected and stored in the biobank for current and future research projects. | |
| Liverpool Research Eye Bank (LREB) | Merseyside | The Liverpool Research Eye Bank (based within the University of Liverpool) is dedicated to advancing our understanding and treatment of ocular diseases. Working in connection with the Liverpool Eye Donation Centre (NHS), we acquire, process and distribute eye tissues for ethically approved research projects in the UK and further afield. | |
| Liverpool University Biobank | Merseyside | The Liverpool University Biobank (LUB) is a multi-discipline biobank set up to consolidate the existing biobanks and tissue collections enabling a centralised approach to the human tissue management and integration of research within the University of Liverpool. It will incorporate retrospective collections of stored samples and prospective collection of new material. | |
| Liverpool University Biobank | Merseyside | The Liverpool University Biobank (LUB) provides researchers with high quality biosamples, data, and analytical services. We house a range of biosamples, and have the ability to collect bespoke samples and data to suit the needs of researchers. We have access to a wide variety of samples types including, but not limited to, frozen tissue, fresh tissue, blood products, urine and FFPE blocks. The LUB can also process samples into a number of products such as DNA, frozen sections, and cryo-aliquots. We also offer additional services such as IHC, next generation sequencing, TMA creation, and project management for studies and projects, to include storage of trial samples. | |
| Liverpool Women's Research Tissue Bank | Merseyside | The Liverpool Women’s Research Tissue Bank (LWRTB) collects and stores biospecimens (including RNA) surplus to diagnostic requirement, from patients undergoing caesarean section, normal delivery or gynaecological procedure, for research. | |
| Manchester Allergy, Respiratory and Thoracic Surgery (ManARTS) Biobank | Cheshire | Collection of samples from patients with respiratory and allergic diseases | |
| Manchester Brain Bank | Greater Manchester | Established in 1986 by Professor David Mann, the Manchester Brain Bank has underpinned much of the basic and clinical research into the spectrum of frontotemporal dementia that Manchester has pioneered over 30 years. The Brain Bank contains around 1,000 brains from patients with various neurodegenerative disorders and from healthy, but elderly, controls. Most brains have formalin-fixed and frozen tissue available for use in approved research. The Brain Bank is also part of the UK Brain Banks Network and uses dissection protocols established by the BrainNet Europe consortium. | |
| Manchester Cancer Research Centre (MCRC) Biobank | Greater Manchester | Facilitating high quality cancer research by bringing a flexible and committed approach to ethical sample and data collection | |
| Manchester Skin Health Biobank | Greater Manchester | The MSHBiobank supports a varied programme of research involving skin and hair disorders. These include chemotherapy induced alopecia, inflammatory hair diseases, other alopecia’s (androgenic alopecia, Female patter hair loss) and skin research including wound healing, psoriasis and skin-related drug side effects. Research programs will aim to provide novel, publishable basic science data and contribute to patient well-being and treatment. Skin and hair samples are stored from patients who are asked to consent to collection of excess tissue left over from routine medical and cosmetic procedures. | |
| Mantle Cell Lymphoma Biobank | Devon | The Mantle cell lymphoma (MCL) biobank opened in 2015, to establish a UK biobank of tumour samples and prospective clinical follow-up on untreated patients with newly diagnosed MCL, in order to develop clinical and biological markers for indolent disease, and establish which patients may undergo a period of watchful waiting before treatment is required. The primary endpoint is defined as time to treatment commencement. | |
| Maternal and Fetal Health Biobank | Greater Manchester | Tissue samples taken from term pregnancies. Maternal blood, umbilical cord blood, urine, myometrium, omentum, breast milk, meconium, amniotic fluid and surface swabs and placental tissues (placental membranes, chorionic plate, placental blood vessels, whole placental cotyledons and villous tissue) | |
| MDSBio | Oxfordshire | Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesis | |
| Mesobank | Cambridgeshire | Mesobank is the UK’s largest collection of high-quality tissue, cells and blood samples from mesothelioma patients. It is dedicated to the study of mesothelioma by providing researchers with samples for a wide range of mesothelioma research. | |
| MFT Biobank | Lancashire | Our biobank is a resource for health research available to all bona-fide researchers via our application process. We hold a large collection of human biological samples with associated clinical information. All human biological samples collected by The Biobank have full ethical approval, and is handled within the conditions of the ethical approval gained, in accordance with the requirements of the Human Tissue Act 2004 and under the governance of the Human Tissue Authority (HTA) Licence (#12552). The Biobank has been ethically approved as a research tissue bank by the NRES Committee North West – Haydock (Ref: 19/NW/0644). The Biobank is authorised to ethically approve biomedical research projects that fall within this governance structure. Researchers receiving samples from The Biobank are not required to have individual project based ethical approval from NRES. Tissue types Uterus (tumour, associated normal, control normal, benign conditions) Ovary (tumour, associated normal, control normal, benign conditions) Colon, ileum (tumour, associated normal, control normal, crohn’s disease, ulcerative colitis) Kidney (tumour, associated normal, control normal) Liver (tumour, associated normal, control normal) Prostate (tumour, associated normal) Thyroid, parathyroid (tumour, associated normal, benign conditions) Head & neck (tumour, associated normal, control normal) Sample types Fresh tissue in perfusion solution (medium of choice available 1hr post-surgical removal) Frozen tissue FFPE (formalin fixed paraffin embedded) tissue blocks Frozen or FFPE tissue sections mounted on glass slides Blood or tissue-derived DNA, RNA and protein Case-matched serum and plasma | |
| Molecular Investigation of Haematopoietic Malignancy Study | Greater London | This study focuses on procuring diagnostic, relapse, remission and progression specimens from Haemato-Oncology patients. This allows researchers to be able to investigate the development and progression of these malignancies in addition to studies into the unique microenvironment. The tissue is stored and equipment maintained to strict guidelines to ensure quality of specimens; the vast majority as single cell suspensions. Also available are samples from the Haemato-Oncology tissue bank which was established in the early 1970s. It is a huge resource containing specimens such as peripheral blood, bone marrow, serum and lymph node biopsies from primarily leukaemia and lymphoma patients. All samples are linked to the clinical outcome of these patients. | |
| MRC/Kidney Research UK National DNA Bank for Glomerulonephritis | Greater Manchester | The glomerulonephritis sample collection consists of DNA samples from Caucasian participants recruited from renal units throughout the UK with one of five glomerular diseases – IgA nephropathy, membranous nephropathy, vasculitis, lupus nephritis and minimal change disease. Trios with Iga nephropathy, control samples and samples from relatives were also collected. Participants were aged 18 years or above. Collection commenced: April 2001 (completed December 2006) IgA Nephropathy (536 cases, 203 controls unrelated, 591 relatives, 222 trios) Membranous Nephropathy (359 cases, 155 controls unrelated, 4 relatives) Vasculitis (457 cases, 219 controls unrelated, 5 relatives) Lupus nephritis (236 cases, 71 controls unrelated, 106 relatives) Minimal Change Disease (153 cases, 59 controls unrelated, 122 relatives, 34 trios) | |
| Multiple Sclerosis and Parkinson's Tissue Bank | Greater London | The Multiple Sclerosis and Parkinson’s Tissue Bank is a national collection of CNS tissue samples donated by individuals with multiple sclerosis (MS), Parkinson’s disease and related neuroinflammatory and neurodegenerative conditions. The Tissue Bank’s mission is to facilitate discoveries by making well-characterised human material of the highest quality readily available to the research community engaged in studies aimed at finding the cause and better treatments for MS and Parkinson’s. Furthermore, we aim to encourage the greater use of the material in scientific studies. It is by carrying out this work that the Tissue Bank fulfills the last, generous and selfless wishes of all those who have registered on the donor scheme and bequeathed their CNS tissues to research. The work of the Tissue Bank is supported by the Multiple Sclerosis Society and Parkinson’s UK in partnership with Imperial College London. | |
| Myeloma XII clinical trial samples | West Yorkshire | Samples collected from myeloma patients at first relapse registered into the Myeloma XII trial, and sent to the following central labs: 1. Central immunology laboratory, University of Birmingham - peripheral clotted blood and urine collected at various timepoints throughout the trial; 2. Haematology Malignancy Diagnostic Service (HMDS) laboratory, St James's University Hospital, Leeds - bone marrow aspirate, collected at various timepoints throughout the trial; 3. Leeds Institute of Cancer and Pathology (LICAP), University of Leeds - peripheral blood, serum, and bone marrow aspirate collected at various timepoints throughout the trial. | |
| National CJD Research & Surveillance Unit (NCJDRSU) BioResource | Midlothian | BioResource for human prion disorders including cerebrospinal fluid, blood, and urine. | |
| National Genomic Research Library | Greater London | The Library is a secure national resource of genomic, health data and samples managed by Genomics England in partnership with NHS England | |
| NephroS: National Study of Nephrotic Syndrome | Bristol | Sample and clinical data collection from adults and children with Idiopathic Nephrotic Syndrome. | |
| Neuromuscular Disorders Research Tissue Bank | Oxfordshire | Oxford Neuromuscular Disorders Research Tissue Bank | |
| Newcastle Biobank | Tyne and Wear | A wide collection of tissue samples, collected for research purposes from patients over the age of 16 presenting to NHS Foundation Trusts | |
| Newcastle Mitochondrial Research Biobank | Tyne and Wear | The Newcastle Mitochondrial Research Biobank (Newcastle MRB) is situated within the Wellcome Centre for Mitochondrial Research, Newcastle University. The collection includes tissue from patients with suspected/confirmed mitochondrial disease, family members of patients with suspected/confirmed mitochondrial disease and tissues from both adults and children who are known to be unaffected by mitochondrial disease (control samples). Samples obtained from patients at post mortem are also stored. | |
| Newcastle Uteroplacental Tissue Bank | Tyne and Wear | The Newcastle Uteroplacental Tissue Bank is a major research resource of human clinical samples obtained, following written informed consent, from non-pregnant and pregnant women (1st, 2nd and 3rd trimester). The bank facilitates research projects conducted with the overall aim to understand the molecular, cellular and tissue remodelling events that occur in the mother and fetus during normal and complicated pregnancies. As such, it is possible for external researchers to access the samples only as part of a collaborative project with one or more custodians of the bank. | |
| NHS Cord Blood Bank | Gloucestershire | We endeavor to minimise waste and process failure in the cord blood supply chain however, inevitably there is donated material that is surplus to clinical requirement or unsuitable for therapeutic use. We are in a unique position to supply this donated material for its own research and development, also to the NHS and to authorised external organisations for specific uses. Non Clinical Issue (NCI) operates on a cost recovery basis, We do not charge for material provided but recovers the costs of making this available. All income is used for the benefit of NHSBT | |
| NHS Greater Glasgow & Clyde Bio-Repository | Glasgow (City of) | The NHS Greater Glasgow & Clyde Bio-repository is part of NHS Scotland NHS Research Scotland Infrastructure. There is a network of Bio-repositories across Scotland designed to encourage use of tissue in research and boost availability of tissue. Each Bio-repository node holds the responsibility for tissue governance for local and partner Health Boards with a main focus on facilitating access to surplus diagnostic and surgical tissue for use in research. | |
| NICAM: Nilotinib treatment for c-KIT mutated advanced AMM | Surrey | Phase II single arm study evaluating the activity of nilotinib in rare c-KIT mutated acral and mucosal melanoma (AMM). Entry into the trial is a 2 step process. Patients presenting with AMM are first registered (Step 1) for screening including confirmation of c-KIT mutation status. Eligible patients who proceed to study entry (step 2) commence treatment with nilotinib 400 mgs twice daily for as long as they continue to benefit from treatment. | |
| NIHR BioResource | Cambridgeshire | NIHR BioResource is a unique and powerful resource for studying disease mechanisms and for investigating the links between genes, the environment, health and disease; enabling scientific discoveries as well as facilitating translational medicine for the benefit of patients. Our mission is to facilitate human health research and its transformation into medical practice. We have over 270,000 consented volunteers, from the general population and patients with common and rare diseases. BioResource volunteers are willing to be recalled according to their genotype and/or phenotype and to participate in academic and industry-led experimental medicine and clinical research studies. Participants who join the NIHR BioResource donate their DNA via a blood or saliva sample which is used together with other information (e.g. gender, ethnicity, health records, genomics), to match them to specific research studies. Genotyping information via high density array is available for most of the BioResource panel, and many of those with rare diseases have whole genome sequencing data available. Where blood samples were taken, plasma, serum and whole blood samples are banked and - along with underlying data - these samples may be requested through our approvals process, see https://bioresource.nihr.ac.uk/using-our-bioresource/apply-for-bioresource-data-access/ As well as healthy volunteers (GEN), the NIHR BioResource has enrolled over 24,000 patients with Rare Diseases (RD), and has four established cohorts, including mental health (MH), Inflammatory Bowel Disease (IBD), Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD, previously known as Non-Alcoholic Fatty Liver Disease - NAFLD) and Immune-Mediated Inflammatory Diseases (IMID). We also created a COVID-19 BioResource which has samples and health data from patients, health workers and visitors to screening pods, vaccination and long COVID clinics. Our newest cohort is the DNA + Young People's Health Resource (D-CYPHR) focused on those aged under 16. Programmes with blood derived banked samples (Plasma, Serum, DNA): General Population 135,000 participants; Genotype array data and Health and Lifestyle questionnaire data available. Inflammatory Bowel Disease (IBD) 45,500 participants; Genotype array data, WES/WGS data, Health and Lifestyle questionnaire data and clinical data available. Immune-Mediated Inflammatory Diseases (IMID) 15,000 participants; Genotype array data pending, Health and Lifestyle questionnaire data and clinical data available. Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD, previously Non-Alcoholic Fatty Liver Disease - NAFLD) 3,500 participants: Genotype array data pending, Health and Lifestyle questionnaire data and clinical data available. Rare Diseases (RD) >24,000 participants; Genotype array data, WGS data, Health and Lifestyle questionnaire data and clinical data available. COVID-19 >8,000 participants; Genotype array data, Health and Lifestyle questionnaire data and clinical data available. Programmes with saliva derived banked samples (DNA): Mental Health (MH) 35,000 participants; Genotype array data, Health and Lifestyle questionnaire data and clinical data available. DNA + Young People's Health Resource (D-CYPHR) >1,000 participants with Health and Lifestyle questionnaire data; Genotype array data pending. Researchers can apply for access to Samples, Data and/or volunteer access (Recall) as specific study requests. Recall could include contacting volunteers with questionnaires or clinical appointments to obtain bespoke samples (from easily accessible sites e.g. urine, skin biopsy) or to take part in activities like an MRI or exercise test. Please contact us if you have a research interest in any disorders or sample types outside of those listed as our core cohorts, we can mine the demographic, genetic and clinical data held to determine if we have suitable candidates for recall to generate the bespoke samples/ data required. Applications are reviewed by a scientific steering committee and delivery timelines will depend on current demand and the complexity of the study. Industry partners may encounter a cost to access NIHR BioResource volunteers. A detailed cost for Industry-led studies can be found at: https://bioresource.nihr.ac.uk/using-our-bioresource/costs/ The Annual Statistics table only lists access requests for banked samples in the March to March period used for HTA reporting, some studies are ongoing requests requiring multiple shipments and are reported in multiple years. A higher proportion of researchers request data access or recall studies than banked samples. We also contribute to the UK LLC and HDR UK (Gut Reaction) national programmes. | |
| NIHR Exeter Clinical Research Facility | Devon | NIHR Exeter Clinical Research Facility is a partnership between the University of Exeter Medical School and the Royal Devon and Exeter Foundation Trust. It is dedicated to facilitation of clinical and translational research. We have two main collections: the Peninsula Research Bank (PRB) and the Royal Devon and Exeter Tissue Bank (RDETB). The PRB has ethics to accept gifted samples from completed studies, and the bulk of the collection is from a dedicated biobank collection called EXTEND (the EXeter TEN thousanD), which aims to recruit one in ten of the local Exeter population. The majority (c. 75%) of our studies are local CI led, and we specialise mainly in diabetes, obesity and related pathologies. However, the majority of people within the EXTEND study are fit and well. The RDETB has overarching ethics to collect samples from diagnostic procedures with patients' consent. Each collection within the RDETB uses a standardised consent and collection approach to obtain material that would otherwise be destroyed or not retained. There is scope for prospective studies recruiting through the RDETB. Both collections have a steering committee controlling access, including lay members from within the biobank. There is a standardised approach for requests and the committee sits once a month. In addition, access to gifted samples within the PRB will involve contact with the PI, where possible. Some studies have additional steering committees where they have been carried out in consortia with other centres. First contact via this directory is encouraged, to establish your needs and our ability to meet them. | |
| NIHR National Biosample Centre (UK Biocentre) | Bedfordshire | The NIHR National Biosample Centre is a not-for profit enterprise supporting NIHR funded researchers across the UK. Control and rights to all samples managed by us remains with the Investigator. We offer at scale storage and processing of bio-samples with the capacity for up to 20 million stored samples in automated storage systems. Additional capacity exists for managed freezer collections and vapour phase liquid nitrogen cryostorage. We provide automated DNA/RNA extraction/normalisation and quantification services as required. | |
| NIHR Nottingham Digestive Diseases Collection | Nottinghamshire | The NIHR Nottingham Digestive Diseases Biomedical Research Unit (NDDBRU) has become the central hub to the gastroenterology and hepatology research within the partnership of University of Nottingham and Nottingham University Trust, bringing together 67 principal investigators bridging basic scientific and clinical fields. Among this large group, we have expertise in a wide range of areas, techniques and methodologies although we focus on early translational studies including pre-clinical and phase I/II studies. We host large deeply phenotyped cohort of patients, linked databases and biological samples. Our academic partnership extends to industry links and we do have experience in developing and evaluating, drugs, devices and health care interventions. NIHR NDDBRU has a mission to take the most promising basic biomedical research breakthroughs and translate them into patient benefit. We focus on developing novel tests, techniques as well as new treatments. We perform experimental medicine investigations into mechanisms underlying disease processes using biological samples from people; we evaluate the efficacy of interventions in volunteers and patients. Our research focus is on ’The infections, inflammation and consequences in the GI tract and liver’. | |
| NIHR St George’s Inherited Cardiac Conditions & Sudden Death Biobank | Greater London | Enhance and facilitate furthering the knowledge and understanding of the psychophysiology, genomics, transcriptomics, risk stratification and development of new treatments in the field of inherited cardiac conditions and sudden death. | |
| NIMRAD-TRANS | Lancashire | A retrospective sample collection of formalin fixed paraffin embedded (FFPE) pre-treatment diagnostic biopsies from patients with Head and Neck Squamous Cell carcinoma (HNSCC) enrolled on the NIMRAD trial. | |
| North East Innovation Lab (NEIL) Biobank | Tyne and Wear | Biorepository of the following samples, collected from COVID-19 positive patients: 1) respiratory swab samples 2) RNA extracts 3) variants of concern 4) blood serum 5) saliva 6) prospectively collected samples. Newcastle upon Tyne Hospitals NHS Foundation Trust | |
| Northern Care Alliance Research Collection (NCARC) | Greater Manchester | The Northern Care Alliance Research Collection (NCARC) is a Human Tissue Authority (HTA) licensed generic research tissue bank with an affiliated sample biorepository operated by Northern Care Alliance NHS Foundation Trust. NCARC was established in 2018 and given ethical permission (Wales Research Ethics Committee 4, REC number 18/WA/0368) to collect, store and release biomaterial and NHS data to support biomedical research. | |
| Northern Ireland Biobank (NIB) | Antrim | Northern Ireland Biobank was established in 2010 to collect, store and distribute human samples for translational research and is primarily funded by the Northern Ireland Health and Social Care Research & Development Division of the Public Health Agency. Cancer Research UK (CR-UK), the Friends of the Cancer Centre and Prostate Cancer UK have also provided financial support. The NIB complies with approvals from both the Office of Research Ethics in Northern Ireland and HSC R&D governance to host and distribute cohorts of quality assured biological samples linked with well-defined clinical and pathological data sets. | |
| Northern Ireland Motor Neurone Disease Biobank | Londonderry | This biobank aims to investigate the potential causes and mechanisms of neural degeneration in patients with Motor Neurone Disease (MND). We will do this by collecting blood and urine samples from patients with MND, some disorders with similar clinical characteristics (e.g Spinal-bulbar muscular atrophy) and healthy controls in Northern Ireland. Study participants may elect to provide optional muscle, skin and cerebrospinal fluid samples. | |
| Norwich Research Park Biorepository | Norfolk | The NRP Biorepository is a newly developing service facilitating world leading research on the Norwich Research park, home to institutes including Quadram Biosciences, the UEA, the Norfolk and Norwich University Hospital, John Innes and the Earlham Institute. Established and funded as part of the development programme of the Park, it supports academic and commercial researchers both locally and from outside the Park in all aspects of tissue based research. | |
| Nostra feasibility trial | West Midlands | A prospective non-randomised, multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies | |
| NovoPath Biobank | Tyne and Wear | The NovoPath Biobank (previously CePA) was established in 2017 as an NHS resource for research. It has full Biobanking REC approval until 2025. It includes provision for access to tissues that are surplus to diagnostic purposes on a prospective basis ‘on request’. It also allows for access to the huge tissue archive of FFPE blocks dating back some 25 years; to give some context to this, currently >200,000 blocks per annum are currently collected and stored. | |
| NRS Lothian Bioresource | Midlothian | The NRS Lothian Bioresource provides access to a wide range of characterised tissue collected in a healthcare setting for use in research. This includes surplus material from diagnostic specimens and surgical procedures. The Bioresource Lothian can facilitate collection of the following material: Pathology archive samples Surplus diagnostic samples - such as blood, urine or other bodily fluids Surplus diagnostic or surgical tissue Bespoke collections of tissue | |
| NURTuRE Residual Bank | Cambridgeshire | NURTuRE is a national kidney biobank, developed through collaboration involving charity, academic and industry, under the strategic oversight and management of Kidney Research UK. NURTuRE includes biological samples (plasma, serum, urine, DNA and tissue) from 3000 patients with Chronic Kidney Disease (CKD) and over 700 patients with Idiopathic Nephrotic Syndrome (INS). Samples are collected and centrally stored under strict Standard Operating Procedures. Data is stored in a Trusted Research Environment (TRE). NURTuRE also contains anonymised linked clinical data, through the UK Renal Registry, as well as Hospital Episode Statistics (HES) and Office of National Statistics (ONS) annual updates. | |
| NURTuRE Residual Bank | Cambridgeshire | NURTuRE is a national kidney biobank, developed through collaboration involving charity, academic and industry, under the strategic oversight and management of Kidney Research UK. NURTuRE includes biological samples (plasma, serum, urine, DNA and tissue) from 3000 patients with Chronic Kidney Disease (CKD) and over 700 patients with Idiopathic Nephrotic Syndrome (INS). Samples are collected and centrally stored under strict Standard Operating Procedures. Data is stored in a Trusted Research Environment (TRE). NURTuRE also contains anonymised linked clinical data, through the UK Renal Registry, as well as Hospital Episode Statistics (HES) and Office of National Statistics (ONS) annual updates. | |
| NURTuRE-AKI: Adult Cardiac Surgery | Bristol | 400 patients undergoing cardiac bypass surgery will be recruited prior to surgery. The study aims to understand why some of these patients will have an AKI (Acute Kidney Injury) and why some go onto develop CKD (Chronic Kidney Disease). Plasma, serum, urine and whole blood will be collected prior to surgery, 1 day, 2 days and 90 days post surgery, alongside clinical data. Long-term outcomes will be collected through linkage to HES/ONS. | |
| NURTuRE-AKI: Adult Cardiac Surgery | Bristol | 400 patients will be recruited prior to having cardiac bypass surgery. The aim of the study is to understand why some patients will have an AKI (Acute Kidney Injury) and why some of these will develop CKD (Chronic Kidney Disease). Plasma, serum, whole blood and urine will be collected prior and post (1 day, 2 days and 90 days) surgery alongside clinical data. Long term outcomes will be obtained by linkage to HES/ONS. | |
| NURTuRE-AKI: Adult Cardiac Surgery | Bristol | 400 patients will be recruited prior to having cardiac bypass surgery. The aim of the study is to understand why some patients will have an AKI (Acute Kidney Injury) and why some of these will develop CKD (Chronic Kidney Disease). Plasma, serum, whole blood and urine will be collected prior and post (1 day, 2 days and 90 days) surgery alongside clinical data. Long term outcomes will be obtained by linkage to HES/ONS. | |
| NURTuRE-AKI: AKI to CKD progression (ACKD) | Northamptonshire | This study aims to establish a prospective cohort of people with AKI (initially 400 patients), in whom stored samples (plasma, serum, spun urine and whole blood) will be collected at time of AKI and at subsequent timed intervals during recovery including long term data follow-up through HES/ONS linkage. | |
| NURTuRE-AKI: Cardiac Surgery (Adults) | Cambridgeshire | This study aims to establish a cohort of adults undergoing cardiac surgery with a high risk of developing AKI post surgery (initially 400 patients). Samples (plasma, serum, spun urine and whole blood) will be collected pre-surgery and at Days' 1, 2 and 90 post surgery. Patients will be followed up for 1 year and then long term data follow-up through HES/ONS linkage. | |
| NURTuRE-AKI: Cardiac Surgery (Paediatrics) | Cambridgeshire | This study aims to establish a cohort of paediatric patients undergoing cardiac surgery with a high risk of developing AKI post surgery (initially 150 patients). Samples (plasma, serum, spun urine and whole blood) will be collected pre-surgery and at Days' 1, 3, 90 and 365 post surgery. Patients will be followed up for 1 year and then long term data follow-up through HES/ONS linkage. | |
| Obesity Research Biobank Syndicate (ORBiS) | Greater London | Bariatric surgery produces substantial, long-term weight loss with reduced morbidity and mortality. Genetics can strongly influence this response, as well as the initial propensity to obesity. Several genes have been implicated but more in-depth mechanistic studies are needed to understand how genes affect energy regulation and mediate the beneficial effects of bariatric surgery. The Obesity Research Biobank Syndicate (ORBiS) aims to fulfil this need. It provides a comprehensive collection of high-quality biological samples and patient data to facilitate mechanistic research and help translate it to improved treatments for patients. Patients undergoing bariatric surgery are recruited from multiple centres in the UK. With informed consent, blood or saliva samples are collected pre-operatively and tissue collected during surgery. Samples include: adipose tissue (subcutaneous and visceral), muscle, liver, stomach and small intestine. Relevant clinical and demographic data are linked and stored pseudoanonymised in a secure database. Tissue collections are transported to and processed in the ORBiS laboratory at University College London, and stored at UCL-Royal Free Hospital Biobank for future use. Research programmes will be supported within and beyond the contributing sites. External researchers will be required to obtain individual REC approval prior to submitting an application. | |
| Ocular Oncology | South Yorkshire | Eye tumours | |
| Ocular Oncology Biobank | Merseyside | The Liverpool Ocular Oncology Biobank (OOB) is a research tissue bank at the University of Liverpool that centralises the collection of biosamples and data from consenting patients with eye cancer who attend the regional specialist Liverpool Ocular Oncology Centre, Royal Liverpool University Hospital NHS Foundation Trust. This is a unique collection from these rare tumours, which provides a high quality resource from which researchers can draw substantial linked collections of material and associated clinical data. | |
| Oncology Clinical Trials Office, University of Oxford | Oxfordshire | OCTO was established in 2002 to run trials concerned with the practical application of high quality research into innovative and effective cancer therapies and prevention strategies. Our portfolio of trials includes a range of projects from first in human drug trials through to large Phase III clinical studies. Studies assess interventions including radiotherapy, drug combinations and novel imaging techniques. Tumour types include: colorectal, oesophageal, melanoma, lung, breast, cervical, haematology, and bone sarcoma, in both adjuvant and advanced disease. | |
| Optimate | Hampshire | The OptiMATe trial is investigating whether a two-step optimisation approach to remission induction therapy with MATRix can reduce toxicity and treatment burden, enabling more patients with PCNSL to proceed to HDT-ASCT and improve survival outcomes. As part of the study, original diagnostic FFPE tumour blocks are collected for central pathology review and extraction of DNA and RNA. CSF samples are collected at baseline for extraction of ctDNA. Further samples will only be collected if there is a positive CSF cytology at baseline. ctDNA blood samples are also collected at 5 different time-points throughout the study (at baseline, during trial treatment and at relapse/progression, if applicable). | |
| OTMC Biobank | Oxfordshire | Biobanking Biological Samples for Research in plasma cell dyscrasias | |
| Oxford Biobank | Oxfordshire | The Oxford Biobank is a local Oxfordshire cohort of participants who have given informed consent to be re-approached for further targeted translational studies, such as recall-by-genotype or recall-by-phenotype studies. The Oxford Biobank consists of random healthy participants (n=8000), patients with type 2 diabetes (n=800), and a recently established work place based COVID-19 research cohort. | |
| Oxford Cell & Tissue Biobank | Oxfordshire | Biobank is located within the Oxford University Hospital NHS Foundation Trust HTA Human Application license no 11106. Retrieves tissue for transplantation and research from living and from deceased persons. Tissue retrieved for Research so far includes: Brain, Spinal Cord, Heart Valve, Eyes, Testicular, Ovarian. This Oxford Biobank service is expanding and will consider requests for retrieval of other cells and tissues | |
| Oxford Musculoskeletal Biobank | Oxfordshire | The Oxford Musculoskeletal Biobank (OMB) is a resource of tissue and blood samples donated by patients for use in medical research (primarily musculoskeletal). The Biobank provides a simple and efficient way to collect and store samples according to regulatory requirements, and it ensures fair access to the samples. Samples will usually be used for research studies which may contribute to increasing the knowledge and understanding of musculoskeletal diseases in order to improve diagnosis and treatment, and ultimately patient care. | |
| Oxford Radcliffe Biobank | Oxfordshire | The Oxford Radcliffe Biobank (ORB) holds a Human Tissue Authority (HTA) licence for storage of human material for research, licence number 12217. The Licence Holder is the University of Oxford and the Designated Individual (DI) is Dr Clare Verrill. The licence covers activities within Oxford, at the main site, the John Radcliffe Hospital, and at the satellite sites, Cowley Store, Churchill Hospital, Nuffield Orthopaedic Centre and Department of Pharmacology. ORB provides infrastructure to underpin biobank activities and delivers a portfolio of integrated services to users, from acquisition, storage and distribution of biospecimens, through to governance, ethical and regulatory cover. The biospecimens and associated information managed by ORB will be used for research studies that may contribute to increasing the knowledge and understanding of disease in order to improve diagnosis and treatment, and could ultimately lead to improvements in patient care. ORB was established in 2006 when a number of active and legacy collections within the University of Oxford and the Oxford University Hospitals NHS Trust were brought together for licensing by the Human Tissue Authority (HTA). This was in response to new legislation, the Human Tissue Act (2004), which came into effect on 1 September 2006. ORB acts as a single gateway for access to the many biospecimen collections held in Oxford. Custodians of collections engage with ORB as part of a federated model. A primary focus of ORB is maintenance of a generic, open-access resource of biospecimens donated by patients and research participants for use in medical research and provision of a simple and efficient system to collect, store, curate, and distribute these biospecimens and associated information. In response to the requirements of the Human Tissue Act, ORB operates a multi-site Human Tissue Authority Research Licence with policies and procedures in place to ensure registered collections comply with the legislation. ORB also provides storage facilities according to HTA guidelines. It is recognised that access to large numbers of high-quality, clinically annotated biomaterials is vital for the advancement of medical research and healthcare delivery. ORB facilitates this access and enhances the research infrastructure by working with all stakeholders to ensure effective sharing of information, resources and best practice. | |
| Oxford Vaccine Centre Biobank | Oxfordshire | A collection of biological samples (genetic material (DNA and/or RNA) and/or serum and/or human cellular material) from healthy volunteers enrolled in clinical research trials of both licensed and novel vaccines, infection challenge models and carriage studies. Samples cover both paediatric and adult populations. The OVC Biobank is managed by staff of the Oxford Vaccine Group, and this group is the primary user of the facility. However, external investigators will also be permitted to deposit samples, including cellular material, for future research related to immunisation, immunity and infectious diseases. | |
| Pancreatic Cancer Research Fund Tissue Bank | Greater London | The Pancreatic Cancer Research Fund Tissue Bank is the world's first national pancreas tissue bank and will accelerate research into pancreatic cancer. The Tissue Bank is funded by the medical research charity Pancreatic Cancer Research Fund, and is a unique collaboration between the charity, Barts Cancer Institute, Queen Mary University of London and six key NHS partners throughout the UK, each renowned for its expertise in treating pancreatic cancer | |
| PANTHER Study | Nottinghamshire | The PANTHER (PANdemic Tracking of Healthcare woRkers) study, is hosted at University of Nottingham, Nottingham University Hospitals NHS Trust and supported by the Nottingham BRC. It aims to deepen the understanding of susceptibility to, immunity from and transmission of Sars-Cov2 (the virus that causes Covid-19) in an at risk population. The PANTHER study measures chemical substances in blood (such as cytokines) that indicate inflammation, and other molecules that fight infection. Additionally, it will study genes to understand if these contribute to the risk of becoming become sick. The PANTHER Study is supported by around 600 volunteers from both hospitals in Nottingham who have been participating in weekly blood draws since the peak of the pandemic and have at the heart of the study a unique resource of rich biological, genetic and other information kindly provided by our cohort of volunteer front line healthcare workers. The study samples are stored in the Nottingham Tissue Bank under a research licence, which is a Human Tissue Authority regulated tissue bank. | |
| Partner Trial | Cambridgeshire | Randomised, phase II/III, 3-stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with triple negative and/or gBRCA sub-type. | |
| PEARLS | Surrey | Blood and stool samples are being collected. | |
| Penile TPF | Greater London | A Phase II non-randomised multicentre trial of docetaxel, cisplatin & 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis. 26 evaluable patients recruited to receive Docetaxel 75mg/m2 day 1, cisplatin 60mg/m2 day 1, 5-fluorouracil 750mg/m2/day (day 1-5), peated at intervals of 21 days. The primary endpoint, measured by RECIST v1, (complete remission rate + partial remission rate). Secondary endpoints are te proportion of patients with inoperable locoregional disease rendered operable by TPF chemotherapy, progression-free survival, overall survival, acute toxicity (as determined by CTCAE) after each cycle and at 3 months and late toxicity (CTCAE). Formalin fixed paraffin embedded tissue samples are held at the Orchid Research Tissue Bank at Barts and the London School of Medicine and Dentistry. | |
| PETReA | Merseyside | Clinical Trial: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma | |
| PHOENIX DDR-Anti-PD-L1 Trial | Surrey | PHOENIX DDR/Anti-PD-L1 Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer | |
| plasmaMATCH | Surrey | The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH) Trial: A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening | |
| Plastic and Reconstructive Surgery Skin and Tissue Bank | Lancashire | The Plastic and Reconstructive Surgery Skin and Tissue Bank collects samples related to a range of skin and tissue clinical conditions including normal and abnormal skin scarring, dudpuytrens disease and breast capsules. | |
| PLATO - Personalising anal cancer radiotherapy dose | West Yorkshire | PLATO (Personalising Radiotherapy in Anal Cancer) is a collection of three clinical studies (ACT3, ACT4 and ACT5) aiming to tailor radiotherapy doses to different situations in patients with anal cancer. At the moment the same treatment (5.5 weeks of daily radiotherapy with chemotherapy alongside) is recommended for all patient with anal cancer irrespective of tumour size or lymph node spread, both of which confer differing chances of cure. Similarly patients experience uniform rates of side effects. We think that some patients might receive more treatment than is optimal; others less. For very small tumours that have been removed with an operation we are then testing the addition of a short course of chemotherapy or radiotherapy (ACT3). For patients with anal tumours less than 4cm in size we are testing whether a shorter course of chemotherapy or radiotherapy gives similar rates of cure to current recommended treatment (ACT4). In patients with more advanced cancers (bigger tumours or evidence of lymph node involvement) we are testing whether higher doses of radiotherapy are safe and more effective at curing the cancer (ACT5). The aligned translational projects that comprise this sample collection aim to better understand the biological features that might also affect how patients’ cancers respond to treatment, and test new ways of monitoring response to treatment to try and improve outcomes. To do this we are collecting samples taken from each patient when they were first diagnosed and analysing the samples for molecular markers that might guide chances of cure. In the group of patients with higher risk disease we are taking additional blood samples before and after treatment and looking for actual cancer cells or DNA shed by the cancer as markers of active disease in the blood. | |
| Plymouth Brain Tumour Bank | Devon | Mainly low grade meningioma and schwannoma fresh-frozen and FFPE tumour tissue samples | |
| POETIC-A Trial | Surrey | POETIC-A: Pre-Operative Endocrine Therapy for Individualised Care with Abemaciclib. Study hypothesis:-To determine the benefit of adding abemaciclib to standard adjuvant endocrine therapy (ET) in a sub-population of ER+/HER2- breast cancer who exhibit early evidence suggestive of suboptimal endocrine responsiveness and high risk of disease relapse | |
| POETIC: Trial of perioperative endocrine therapy – individualising care | Surrey | Primary aim: To determine whether two weeks perioperative aromatase inhibitor (AI) therapy before and after surgery improves outcome compared with standard adjuvant therapy. Eligibility: Postmenopausal women with ER/PgR positive invasive breast cancer. Trial design: Phase III, multicentre, randomised trial Target accrual: 4350 patients Patients will be allocated in a 2:1 ratio to PERIOPERATIVE THERAPY with an AI for 4 weeks (two weeks before and two weeks after surgery) or NO PERIOPERATIVE THERAPY. Group I: PERIOPERATIVE THERAPY with an AI Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day) Group II: NO PERIOPERATIVE THERAPY 4 weeks (two weeks before and two weeks after surgery) | |
| PORT Trial | Greater London | Skin biopsies will be obtained from patients for translational studies to identify biomarkers of immunological response to the combination of pembrolizumab and radiotherapy in patients with advanced Cutaneous T Cell Lymphoma (CTCL). | |
| POUT-T | Warwickshire | POUT-T: The translational substudy of a phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer. The objectives of POUT-T are: to investigate the molecular pathogenesis of Upper Tract Urothelial Carcinoma (UTUC); to identify prognostic and predictive biomarkers of UTUC; and to identify diagnostic biomarkers of UTUC. POUT-T participants are requested to provide the following specimens pre-operatively, post operatively, 6 months following surgery, and at disease recurrence: whole blood for germline DNA analysis; whole blood for cell-free DNA analysis; first moning urine for DNA, proteome and metabolome analyses. In addition, paraffin-embedded tumour tissue from nephro-ureterectomy is requested for immunohistochemistry and DNA/RNA analyses. | |
| PTCL Biobank | Leicestershire | An Observational Study of Peripheral T cell Lymphoma: Establishment of a Biobank and Database. The outcome of this study will be a biobank of PTCL cases with linked clinical data and serum, saliva and plasma samples to enable assessments of treatment response and prediction of relapse. | |
| Public Health England Seroepidemiology Unit | Lancashire | The basis of the PHE (formerly the Health Protection Agency) Seroepidemiology Programme is a large collection of sera representative of the general population of England, forming a unique and valuable public health resource. The collection is stored and maintained by the Seroepidemiology Unit (SEU) at the Public Health Laboratory (PHL), Manchester. Sera submitted to the SEU are residues of specimens submitted for diagnostic testing. They sample the population range and are anonymised prior to archiving (retaining age, sex, date of collection and source laboratory only). Collection of sera is continuing through collaboration with the PHE Microbiology Services Division (MSD) and some NHS laboratories throughout England, and has occurred annually since 1986. Over 230,000 sera are now stored and catalogued. The collection can be made available for testing to anyone wishing to use it to address issues related to public health policy. | |
| QTL Programme at MRC HGU | Midlothian | The QTL (Quantitative Trait Locus) programme is based at the MRC Human Genetics Unit in the University of Edinburgh. The research programme uses the unique population structures in our Scottish and Croatian cohorts to deliver biological understanding of the causes of variation in complex traits. Together, the ORCADES and VIKING biobanks contain 4,000 samples from volunteers with ancestry from the Northern Isles of Scotland, www.ed.ac.uk/viking. Collectively, the CROATIA cohorts contain 6,000 participants. All of these biobanks were constructed from people with high kinship and extensive pedigree structures. They were collected together with detailed phenotype data, some of which is longitudinal. Plasma, serum, urine and DNA samples, as well as detailed genomic, proteomic and metabolomics data can be made available for collaborative research. | |
| Quality in Organ Donation (QUOD) | Oxfordshire | The Quality in Organ Donation (QUOD) initiative facilitates research into organ donation and transplantation by providing researchers with samples and clinical data from appropriately consented / authorised DCD and DBD organ donors. We have over 90,000 biosamples from over 5,000 organ donors available for biomedical research. We can provide blood, urine and BAL samples, and tissue biopsies (left and right kidneys, liver, ureter, spleen, heart). Samples will be available to research projects based on scientific merit. Visit our website to apply to access our samples. | |
| QUANTUM Research Tissue Bank | Oxfordshire | QUAlity biobanking iNvesTigating Urological Malignancies | |
| Queen Mary University of London | Greater London | Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting, conducted by the Transatlantic Prostate Group (TAPG) is a long-term retrospective epidemiology cohort study on factors predicting clinical progression of prostate cancer. The TAPG study started in 1999 and comprises approximately 3,300 men diagnosed with prostate cancer between 1990 and 2006. This exploratory study aims to identify prognostic markers that will more accurately predict the probability of recurrence and allow for better patient selection for radical treatment of prostate cancer. | |
| RADAR (UK-MRA Myeloma XV) | West Yorkshire | - | |
| RAPPER | Lancashire | RAPPER (Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy) is a national radiogenomics study investigating the association between common genetic variation determined by single nucleotide polymorphisms (SNPs) and radiation toxicity. | |
| Rare Cardiovascular Disease Biobank | Greater London | The Rare Cardiovascular Diseases Research Tissue Bank is a repository of blood, urine and tissue samples collected from paediatric patients under the care of the cardiology team at Great Ormond Street Hospital. The Biobank is managed by the UCL Institute of Cardiovascular Science. For the purposes of this biobank, rare cardiovascular diseases include inherited and acquired cardiomyopathies, inherited arrhythmia syndromes, aortopathies and pulmonary hypertension. Biobank samples are collected from: patients diagnosed with a rare cardiovascular disease, patients carrying genetic variants which increase their risk of developing a rare cardiovascular disease, or patients undergoing cardiac screening due to a family history of one of these conditions. The aim of this Biobank is to facilitate research into rare cardiovascular disease in children. | |
| Rarecan | Northumberland | The RareCan Bioresource has been established to accelerate research into rarer forms of cancer- ie those with an incidence of less than 10 per 100,000. This includes both rare histological entities and rare subgroups within common tumours- for example those with unusual molecular characteristics. We are building up our repository of frozen tissues with matched frozen blood and formalin fixed paraffin embedded blocks but can also collect samples “to order”. We have overarching NHS research Ethics approval for research projects using samples collected by the bioresource. | |
| RATHL Trial | Greater London | RATHL is a multicentre, randomised, phase III trial comparing treatment outcome for patients with advanced Hodgkin lymphoma, using FDG-PET imaging after 2 cycles of ABVD to determine response and subsequent management. Recruitment target: 1200 patients Patients received 2 cycles of ABVD and then had a PET-CT scan. PET negative patients were randomised to either ABVD or AVD for a further 4 cycles. PET positive patients received either BEACOPP-14, for 4-6 cycles or BEACOPP escalated, for 3-4 cycles. Samples collected for trial: Formalin fixed paraffin embedded tumour block - sent to HMDS, Leeds. Blood sample to be analysed at site. Blood sample - sent to Simpson Centre for Reproductive Health, Edinburgh. | |
| RE-AKT | Surrey | A multicentre prospective, randomised, phase II interventional study in mCRPC patients previously treated with 1-2 lines of chemotherapy and at least 12 weeks of abiraterone with a safety run-in and single stage phase II expansion cohort | |
| RE-ARM Trial | Surrey | A Randomised phase II trial of Enhancement of efficacy of Atezolizumab by Radiotherapy in Metastatic urothelial carcinoma | |
| Registry of Autoimmune Rheumatic Diseases | Surrey | The registry of autoimmune rheumatic diseases involves the standardised collection of blood and clinical information from individuals with several diseases such as lupus, rheumatoid arthritis, scleroderma, vasculitis, Sjogren's syndrome, polymyositis, and dermatomyositis, as well as patients with antiphospholipid syndrome. The great advantage of the registry is that it can provide researchers with complete sets of clinical blood samples to answer important clinical questions, helping to facilitate the integration and analysis of clinical and biological data. | |
| REMoDL-A Trial | Hampshire | The REMoDL-A clinical trial evaluates the addition of acalabrutinib to standard of care therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-Cell Lymphoma (DLBCL). As part of the study, original diagnostic FFPE tumour blocks are collected for gene expression profiling and central pathology review using IHC and FISH analysis. Tissue microarray blocks may also be produced if there is sufficient tissue left in the diagnostic FFPE tumour block. ETDA blood samples are collected at baseline before administration of any study drugs and ctDNA blood samples are also collected at 8 different timepoints throughout the study (at baseline, during trial treatment and during follow-up). | |
| REPROCELL Europe Ltd | Glasgow (City of) | REPROCELL Europe Ltd is a Contract Research Organisation specialising in the use of fresh human tissues to better predict drug efficacy and safety during non-clinical drug development. We source a range of fresh healthy and diseased tissues from multiple providers, across the UK, Europe and the USA, for specific academic and pharmaceutical industry sponsored projects conducted within REPROCELL facilities. Services utilising fresh tissue include pharmacological assays, 3-D culture and induced pluripotent stem cell production using our exclusive RNA re-programming technology. Through our REPROCELL partner group we also have access to a global biorepository of human serum, DNA, RNA and FFPE samples. | |
| REQUITE | Lancashire | Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors. The purpose of this international study is to try to predict which patients are more likely to have side effects from radiotherapy. Funded by the European Commission FP7 HEALTH scheme. | |
| REQUITE database and biobank | Leicestershire | The REQUITE project was an EU-funded, prospective, observational study which ran from 2013-18 (Seibold et al 2019). Manchester University was the research sponsor, with primary ethics approval given by the North West England REC with IRAS project ID 143488 and REC reference: 14/NW/0035, with secondary ethics approvals in other countries. REQUITE’s aim was to collect blood samples and clinical data from cancer patients treated with radiotherapy with curative intent, with the primary objective being to find factors affecting risk for radiotherapy side effects. Patient recruitment took place between April 2014 and March 2017 in 26 hospitals in eight countries (UK, Germany, France, Italy, Spain, Belgium, USA and Netherlands). Two UK centres were included as hubs in the project: Manchester and Leicester, with some patients also recruited in satellite hospitals in Nottingham, Derby and Salford. The study recruited 2071 breast, 1808 prostate and 561 lung cancer patients. Clinical data was collected using standardised data collection forms pre-radiotherapy, after-radiotherapy and at one- and two-years’ time-points post treatment. Both clinician and patient reported radiotherapy side effect data was collected. Blood samples were drawn pre-treatment only. Radiotherapy planning CT scans (DICOM files), organ dose-volume histograms and breast photographs were stored. At the current time the biological sample collection for the REQUITE cohort held at the University of Leicester consists of: 866 blood samples collected in PAXgene RNA tubes (2.5ml of blood + 6.9ml preservative) 4438 DNA samples (normalised concentration at 100ng/µl, volume 48-590µl) 4419 DNA samples (variable concentration stocks, volume 8-1000 µl) The content of the database consists of records for a total of 4438 radiotherapy patients, of which 2069 are breast cancer, 1808 prostate cancer and 561 lung cancer patients. The data held includes baseline information on: Cancer treatment o Surgery type o Chemotherapy regimen o Radiotherapy technique o Total radiation dose and fractionation Technical medical physics data o Radiotherapy planning CT scans saved as DICOM files (regional scans i.e. thoracic for breast & lung cancer patients, abdominal for prostate cancer) o 3D radiation dose distribution saved as RTPlan file o Organ delineations on CT scan saved as RTDose and RTStruct files o Dose-volume histograms for each organ-at-risk (these quantify the volume of each organ exposed to particular doses of radiation) And multiple time-point (for all patients pre-radiotherapy, 3 weeks and 1 year post radiotherapy, for breast and prostate patients also at 2 years, and on a sub-set of patients to 6 years after treatment) data for: Medical (e.g. age, comorbidities, BMI, prescription medications) Physician reported radiotherapy side effects (CTCAE v4.0) Patient reported radiotherapy side effects Quality of life questionnaire Laboratory data that was generated during the REQUITE project is also held in the database: Imputed SNP genotype data on 4409 patients Radiation-induced lymphocyte apoptosis assay data on 1319 patients (only patients recruited in Mannheim, Montpellier and Leicester) | |
| Research Donors Ltd | Greater London | For researchers Blood collection We collect blood from donors aged between 18-60, who have been screened to ensure that it is safe for them to donate, that they are in good health, and not taking medications that might interfere with experiments. Donors will have given consent for their samples to be used in a wide range of biomedical research applications, including genetic research and that undertaken by commercial organisations. We are also able to collect samples from specific donors, for example within a certain age range, ethnicity or with a specific blood group. We can collect samples into a wide range of anticoagulant tubes, blood bags and other devices as required. Processing We use advanced technologies in our laboratory to test donated blood samples and to process them into the formats which are most useful to researchers. These include: Whole blood From a single tube of whole blood in a specific anticoagulant tube, up to a full bag of blood we can collect the exact volume of blood you need from donors best suited to your study and deliver it within precisely defined timeframes at the best temperature for your need. Buffy coat We routinely process whole blood units into buffy coat preparations which are used as a source of PBMCs by our clients. We can also process smaller volumes of blood from blood collection tubes into buffy coat. Plasma We can either collect a specific volume of blood in the anticoagulant of your choice and prepare plasma, or you can source plasma samples that we have banked from a wide selection of donors for screening purposes. Serum We can either collect a specific volume of blood and prepare serum to suit your needs, or you can select from serum samples that we have previously banked from a wide selection of donors. PBMCs We are preparing PBMCs from whole units of blood within a very short timeframe from venepuncture (typically processing begins within 1 hour). PBMCs are produced using a density centrifugation, characterized and frozen in a proprietary freezing solution designed to maximise cell viability. Custom services We can develop specific processes to suit your exact requirements, so please get in contact if there is something specific you need for your research | |
| RIO | Surrey | Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) | |
| RJAH Biobank for Health and Disease | Shropshire | Biobank for orthopaedic tissue, including bone and soft tissue sarcoma | |
| RJAH Biobank for Studying Health and Disease | Shropshire | Orthopaedic tissues Wax embedded and fresh frozen tissues of primary and secondary bone tumour and ssarcoma and metastatic disease. If a certain tissue types are required with the correct Ethics and consent in place these could be collected and stored at the tissue bank. | |
| RM PCa Research Tissue Bank | Greater London | The Research Tissue Bank will hold a mix of existing biological material collected from prostate cancer patients as part of the routine clinical care pathway and samples collected specifically for future research. Retrospective samples: - Formalin-fixed paraffin-embedded tissue taken from the primary tumour (and metastases if clinically-indicated) at the point of routine standard of care biopsy Prospective samples: - Whole blood - Saliva - Urine | |
| ROCkets/ROCkeTS-GEN | West Midlands | The ROCkeTS study is a diagnostic study which aims to validate new tests/risk prediction models that estimate the probability of having ovarian cancer in pre and post-menopausal women with symptoms. The ROCkeTS-GEN substudy is also a diagnostic study but only recruiting post-menopausal women with the aim of evaluating patients' circulating tumour DNA (ctDNA) using genome sequencing to determine if ctDNA can be used as a diagnostic biomarker and thus improve the sensitivity of detecting ovarian cancer. | |
| ROH Research Tissue Bank | West Midlands | The research tissue bank has been set up to collect samples such as; bone and soft-tissue sarcomas, metastatic carcinomas, blood, bodily fluid and other normal tissues (i.e. skin, muscle, adipose tissue, cartilage, bone marrow etc.). Associated anonymised data can be provided including information from medical notes, validated questionnaires and images as well | |
| Royal Brompton & Harefield hospitals | Greater London | Collection of blood, plasma, serum, saliva, urine and tissue samples from patients with cardiovascular disease. The collection contains both prospectively collected samples and archive material. | |
| Royal Marsden Hospital NHS Foundation Trust | Greater London | IReC-Bio will act as a central repository for rare recurrent head and neck cancers which will be used to support translational research. | |
| Royal Papworth Hospital Research Tissue Bank | Cambridgeshire | We collect all tissue arising from cardio-thoracic procedures, including, but not limited to: aorta, myocardium, heart valves, cardiac and peripheral vessels, lung, airways, blood vessels pulmonary,blood, sputum and tumour samples. We also provide relevant routine clinical data such as previous medical history and certain treatment details. | |
| RxCelerate research biobank | Cambridgeshire | Plasma and serum samples from patients with atherosclerosis and assumed healthy controls | |
| SAFIR ABC-10 Precision Medicine Clinical Trial Samples | Greater London | Tumour tissue: Where possible, a tumour tissue sample will be obtained from each patient at the time of enrolment into the screening phase of the trial for translational research objectives. This will be a sample harvested prior to the initiation of first line standard of care therapy (this can include archival tissue), or where this is not possible, a pre-treatment biopsy during Cycle 1 of first line standard of care. For patients treated with molecular targeted therapy, where medically feasible, a second biopsy will also be performed in consenting patients at the time of relapse or disease progression to collect a treatment-resistant tumour sample. Blood samples: For patients who participate in the Screening phase and Randomised trial, blood plasma samples are to be collected at the following time points: - At entry to the Molecular Screening Phase of the trial - During the baseline selection period for the Randomised trial - Post-randomisation Visit 4 (Day 64 (±3) post-randomisation) - At disease progression For patients in the control arm who cross-over to receive MTT in 2L, additional plasma samples are to be collected at the following time points: - Cycle 4 Day 1 of cross-over MTT therapy - At disease progression (2L) For patients who participate in the Screening phase only (i.e. those who are not eligible, or decline to participate in the randomised trial), plasma blood samples are to be collected at the following time points: - At entry to the Molecular Screening Phase of the trial. - At Cycle 5 Day 1 of 1L-SoC, or at disease progression if this occurs earlier Whole blood samples will be collected at entry to the Molecular Screening Phase of the trial only. | |
| School of Cardiovascular Medicine & Sciences Biobank and repository | Greater London | The School of Cardiovascular Medicine & Sciences Biobank involves the standardised collection of tissue, blood and clinical information from individuals who might have diseases in the arteries, veins and the heart, as well as from healthy controls. The great advantage of the Biobank is that it can provide researchers with complete sets of clinical data, tissue and blood samples to answer important clinical questions, helping to facilitate the integration and analysis of clinical and biological data. In turn, by having a Biobank of samples/clinical data available, individual participants are exempt from the burden and the stress of being asked to donate samples on more than one occasion. | |
| Scleroderma and Raynaud's Research Bank | Greater Manchester | The Scleroderma and Raynaud's Research Bank (SRRB) consists of a Bank of blood, DNA, serum, skin biopsies, calcinosis samples and capillaroscopy and thermography images with associated clinical data. These are collected on patients with scleroderma (both systemic sclerosis spectrum disorders including localised scleroderma also termed morphoea), patients with other connective tissue diseases, patients with primary Raynaud’s phenomenon, patients with shoulder problems leading to deposition of calcium salts (deposition of calcium salts also occurs in scleroderma) and healthy controls. The Bank currently contains samples from over 800 individuals, collected as part of individual research projects and the ongoing assessment of patients attending general rheumatology, scleroderma and dermatology clinics acting as tissue collection centres. | |
| SCOT translational sample collection | Glasgow (City of) | The SCOT study enrolled more than 6000 patients over a 5 year period and is the largest single trial ever conducted in CRC. Tissues collected from patients entered in to the study are physically hosted in two sites; blood samples and blood fractions e.g. DNA, are held at the University of Oxford and FFPE samples are housed at the Glasgow Biobank. There are approximately 3000 blood and 3000 tissue samples in the collection. The associated clinical data is held by the Cancer Research UK Clinical Trials Unit, Glasgow. | |
| Scottish Brain Health Bioresource (EPAD and Prevent Dementia) | Midlothian | In order to understand and track early disease progression the European Prevention of Alzheimer’s Dementia (EPAD) consortium, the largest public-private partnership in the history of AD research, established a European-wide Longitudinal Cohort Study (LCS) that screened over 2,000 participants and collected a wide range of cognitive, clinical, neuroimaging and biomarker data. Although the EPAD LCS closed in 2019 the bioresource remains which contains over 100,000 samples including, blood products, saliva, urine and Cerebral Spinal Fluid (CSF), all collected from EPAD participants, which can be used to further our understanding of neurodegenerative disease. EPAD consent signed by the participants covers sample storage for at least 15 years and use by local (The University of Edinburgh and other scientists for additional research in the future. Also, information that could be obtained from the analysis of EPAD samples may be used scientifically and may be used in other research. The Bioresource has also recently added samples from the Prevent Dementia and EPAD Scotland studies and these will soon be available to researchers. | |
| Scottish Early Rheumatoid Arthritis (SERA) | Glasgow (City of) | The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers. | |
| SFH/UoN Human Joint Tissue Repository | Nottinghamshire | The repository is donated by participants at Sherwood Forest Hospitals NHS Foundation Trust, Nottinghamshire, UK (SFH, Sponsor) from 1999 to the present day. Currently we hold:- Samples from people undergoing arthroplasty (total joint replacements) Samples donated post-mortem • snap-frozen synovium • fixed joint tissues (paraffin wax-embedded, Zambonis-fixed for cryosectioning) -synovium -cartilage and bone -meniscus -tendons -muscle • un-fixed synovium for cryosectioning • serum • synovial fluid • dorsal root ganglia and spine SOPs and ethical approval for prospective collection of synovial tissue, bone/joint tissue and biofluids are in place, and we currently obtain consent annually from >100 people undergoing arthroplasty per annum and >40 post-mortem donor families. Our participants and donors have consented for samples and anonymous data to be provided to industrial partners for commercial research, both within and outside the UK. Our holdings include extensive clinical data such as joint examination, weight-bearing radiographs, chondropathy scores, medications and demographics. We have recently commenced routine baseline collection of patient-reported outcome data (n>300 people to date), including pain phenotyping and other symptoms, and we are able to send postal surveys for follow up data collection. | |
| SHARE (Scottish Health Research Register and biobank) | Angus | The Scottish Health Research Register SHARE adopts an approach which asks the public to consent to their data held in NHS databases to be used to determine their suitability for research projects. Additionally participants can consent for spare blood, left after routine venepuncture to be stored for future research studies. This has been implemented in tayside and Grampian with over 50,000 blood samples intercepted by March 2017. Anyone over the age of 11 years in Scotland can participate. Participants are approached through a range of methods including directly at out-patient clinics and GP practices, leaflets with hospital letters and personal email from employers. SHARE has recruited around 150,000 people, with over 95% of all individuals providing consent for the use of spare blood. SHARE has demonstrated that it can quickly and efficiently recruit to studies. In addition it can be used to administer questionnaire studies by email and recruit to patient and public involvement groups. SHARE continues to steadily recruit with the ambition of eventually achieving 1,000,000 people in Scotland. We are steadily extending the datasets we use for identifying participants. We are adding a mobile APP which will facilitate dissemination about research and allow the collection of physiological and activity data if desired. We anticipate SHARE will soon become the main source of health research recruitment in Scotland. Cohort description paper: PMID: 28148535 | |
| Sheffield Brain Tissue Bank | South Yorkshire | We are a post mortem CNS tissue bank that focusses on neurodegenerative diseases and ageing. | |
| Sheffield Brain Tissue Bank (SBTB) | South Yorkshire | Sheffield Brain bank comprises of tissue samples mainly of Degenerative diseases (MND, Alzhiemers) | |
| Sheffield Collaborating Centre of the Breast Cancer Now Tissue Bank | South Yorkshire | The University of Sheffield collects malignant and normal breast tissue and blood samples from patients attending the Royal Hallamshire Hospital and Weston Park Hospital, Sheffield as part of a research project led by Prof. Angela Cox; "The role of angiogenesis and genome stability in breast cancer, and biosample collection". The research group specialises in the collection of longitudinal blood samples, including blood plasma for circulating DNA applications, serum and viable cells. Patients are invited to donate their samples to the Breast Cancer Now Tissue Bank (BCNTB), a ground-breaking, multi-million pound initiative linking four centres around the country which work together as one national resource. The BCNTB represents the UK’s single largest unique collection of high-quality breast tissue samples. The Breast Cancer Now Tissue Bank samples are held in the Tissue Bank at Queen Mary University of London (the Lead Operations Centre). Institutions which have been appointed as the Collection Centres are the University of Aberdeen, the University of East Anglia and the University of Sheffield. | |
| Sheffield Lung Research Tissue Bank | South Yorkshire | Closed | |
| Sheffield Pulmonary Hypertension Biobank | South Yorkshire | Longitudinal collection of blood samples from patients with pulmonary hypertension and associated lung and cardiovascular disease, as well as some healthy volunteers as controls. The biobank samples with associated clinical data are used in research into the these conditions, how they cause symptoms and illness, and to develop new ways to diagnose, treat, and prevent diseases. | |
| South West Dementia Brain Bank and DNA Bank | Avon | The South West Dementia Brain Bank (SWDBB) is housed within the Learning & Research Building at Southmead Hospital in Bristol. It is licensed by the Human Tissue Authority and has approval from the South West - Central Bristol Research Ethics Committee to operate as a Research Tissue Bank. The SWDBB opened for the receipt brain donations for dementia research in the mid-1980s. In 2010, it became one of the recruitment centres and member brain banks in the ABBUK-funded Brains for Dementia Research (BDR) project. BDR involves prospective donors undertaking annual assessments and providing clinical information including details about their memory and thinking skills over time, as well as comorbidities and genetic information from the time they register until the time of their eventual donation. This process provides a rich amount of information on which to base future diagnosis but also for information that will be of great importance in informing future research studies. The SWDBB holds brain tissue from over 1200 people. Each donation has been characterised systematically and neuropathically diagnosed by an approved clinician according to international guidelines. Frozen and formalin-fixed paraffin-embedded tissue and DNA are available from most of our donors, as is other information that has been systematically collected in relation to Aβ and tau pathology, cerebral amyloid angiopathy and small vessel disease severity, and tissue pH. For a subset of SWDBB donated brains we also have frozen samples of post-mortem ventricular cerebrospinal fluid. Additionally, we hold the medical records of our donors and can provide detailed, anonymised clinical data either via a data-only request or as part of an associated tissue request application. Details of samples available from all cases held by the SWDBB can be found and searched for in the UK brain banks network: database of tissue samples at: https://brainbanknetwork.ac.uk/ | |
| South Yorkshire and North Derbyshire Musculoskeletal Bio Bank | South Yorkshire | The SYNDMB collects, stores and distributes tissue samples as necessary to deliver tissue to approved research projects. This may include the collection of samples from donors with rare conditions or characteristics of special interest for use in future research that is not yet defined. The SYNDMB may accept a wide range of samples and data obtained from donors, or completed, ethically approved projects with appropriate consent for Biobank storage, in South Yorkshire and North Derbyshire, elsewhere in the UK and internationally (including countries outside the EEA) | |
| Southampton Clinical Trials Unit | Hampshire | The Southampton Clinical Trials Unit (SCTU) is a UKCRC registered CTU with expertise in the design, conduct and analysis of multicentre interventional clinical trials. We work in partnership with investigators to deliver high quality trials that will directly influence routine clinical practice. | |
| Southampton Research Biorepository (SRB) | Hampshire | The Southampton Research Biorepository (SRB) is funded by the NIHR Clincial Research Facility to provide a local infrastructure within which biological samples can be collected and securely stored, in addition to a regulatory framework and administration system to coordinate delegated NHS research ethics approval. The following types of studies are eligible for application to the SRB for NRES approval: - Studies using tissue samples collected as part of routine NHS care (surplus to diagnosis tissue). - Studies applying for tissues already held within the SRB. Additionally, study teams may apply to the SRB to prospectively collect and house tissues in the SRB for use in future research studies. - Samples collected from patients, acquired for banking for use in future research studies. - Samples collected from healthy participants, acquired for banking for use in future research studies. - Pilot studies and studies from investigators across the University are welcome. For application forms and further advise please contact SRB@uhs.nhs.uk | |
| St Thomas' Hospitals Plasma, serum & DNA Bio bank from patients with antiphospholipid antibodies | Surrey | A frozen biobank collection of plasma, serum, and DNA from APS patients. Each sample is anonymised blood sample collected from patients who consent for its use in future research into Antiphospholipid Syndrome. APS is defined as the association of antiphospholipid antbodies (aPL) with arterial or venous thrombosis and /or pregnancy morbity. Antiphospholipid syndrome is an autoimmune disorder in which aPL are involved in the development of venous and/or arterial thrombosis. | |
| STAMPEDE | Greater London | tbc | |
| STAR-TREC | West Midlands | Population: Patients with biopsy proven adenocarcinoma of the rectum, staged as TX/T1/T2/T3, NX/N0, MX/M0 via MRI or ERUS, ECOG PS 0-1, choosing an organ preserving treatment and randomised to receive either long-course chemoradiotherapy (Radiotherapy 25x2Gy plus concurrent capecitabine 825 mg/m2 bd on radiotherapy days over 5 weeks) or short-course radiotherapy (5x5Gy over 5 days). Patients showing tumour progression, poor or no response to (chemo) radiation at 11-13 weeks will undergo Total Mesorectal Excision (TME) surgery. Patients showing incomplete response at 16-20 weeks will undergo Transanal Endoscopic Microsurgery (TEM). Identification of high-risk histopathological features in TEM specimens will prompt conversion to TME. Samples taken: A) Blood derived ctDNA obtained at randomisation, week 16-20 and 6, 12, 18 and 24 months from the start of (chemo)radiotherapy. B) Formalin-fixed paraffin embedded tissue blocks obtained from the biopsy specimen taken to confirm presence of rectal adenocarcinoma and from any subsequent surgical procedure (TEM and/or TME) required to excise the tumour. | |
| SUN Study | Surrey | The SUN study is a Bio repository of 6 monthly sequential blood samples from 350 men with Prostate Cancer - pre-treatment and through follow-up | |
| SWIFT-RTB | Cardiff | Fetal tissue | |
| Synairgen Respiratory Tissue Bank | Hampshire | The Synairgen Respiratory Tissue Bank is a collection of samples including serum, sputum, nasal lavage, primary bronchial epithelial and fibroblast cells collected from volunteers with asthma, COPD and age matched controls as part of Synairgen's ongoing respiratory research programme. | |
| Tayside Biorepository | Angus | Tayside Biorepository is an established bio-resource responsible for the provision of a wide range of human tissue from consenting patients in addition to providing a large range services including staining and extraction methods. | |
| The Airwave Health Monitoring Tissue Bank | Greater London | The Airwave Health Monitoring Study was established in 2003 to evaluate possible health risks associated with the use of TETRA, a digital communication system used by the police forces and other emergency services. It is a long-term observational study following up the health of police officers and staff across Great Britain, with the ability to monitor both cancer and non-cancer health outcomes. Around 53,000 participants have been recruited between June 2004 and March 2015 with a response rate averaging 50% of employees in participating forces. At baseline, participants completed an enrolment questionnaire (sent via routine administration or the occupational health service), or a comprehensive health screening performed locally, or both. Around 85% (N=45,000) of the cohort received a health screening. Clinical and biological measurements were taken, blood and urine samples collected. Participants were 40 years old on average (between 17 and 80 years old at inclusion), mostly men (63%) and white British (85%). A second assessment of participants living in England started in November 2015 and is ongoing. We aim to recall 40%+ of the original cohort for a second clinic visit, at least 5-years following their enrolment. | |
| The Cleft Collective | Avon | The Cleft Collective is a longitudinal cohort study looking to investigate the biological and environmental causes of cleft and the best treatments of cleft on those affected and their families. The study comprises two separate cohorts, a Birth Cohort and a 5-year-old Cohort. The birth cohort is further split into two sub-groups, postnatal and antenatal, allocation to these groups is determined by the time of recruitment. Recruitment to the two cohorts is currently ongoing across the UK. A large amount of phenotypic and environmental exposure data is being collected via questionnaires and record linkage. A data dictionary, available on the study website, contains details of all the available data. As a minimum, biological mother and affected child are recruited to the study. Where possible, biological father or mother’s partner is also recruited. In addition, the study aims to recruit unaffected and affected siblings for a small proportion of the cohort. Biological samples are collected from all participants. Parents and siblings of both cohorts and affected children of the 5-year-old cohort provide saliva samples. Residual tissue and blood samples are collected from affected children recruited to the birth cohort. In addition, cord blood samples are collected from families recruited to the antenatal strand. | |
| The Continuum Biobank | Swansea | The purpose of the Continuum Tissue Bank is to understand how our bodies work to fight cancer so we can improve diagnosis and design better treatments. Our Tissue Bank will supply scientists who are undertaking cancer research to gain a better understanding of the biological mechanism that allow unique individuals to survive multiple cancers. The biobank collects blood samples from donors who have survived multiple cancers. Frozen peripheral blood mononucleated cells (PBMCs) and plasma are stored for these donors and healthy controls with no family history of cancer. | |
| The Genetic Beta Cell Research Bank (GBCRB) | Devon | The Genetic Beta Cell Research Bank (GBCRB) is a tissue bank with over-arching ethics to carry out research into the mechanisms and genetic causes of diabetes and other beta cell disorders. It stores samples from diagnostic archives and residual samples from research activity where enduring consent has been given. The GBCRB ensures effective guardianship of these samples, with a Steering Committee that reviews all requests to use samples and associated data to ensure they are sensibly used to improve the diagnosis, care and treatment of genetic diabetes. | |
| The Institute of Transplantation Tissue Biobank | Tyne and Wear | The Institute of Transplantation Tissue Biobank draws on the strength of the NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation, and the Freeman Hospital, the only hospital in the country to transplant all major solid organs. We are able to recruit patients from all stages of the transplantation journey and receive material from organ donors. | |
| The John Walton Muscular Dystrophy Research Centre Biobank | Tyne and Wear | The John Walton Muscular Dystrophy Research Centre (JWMDRC) Biobank located at the International Centre for Life (Translational and Clinical Research Institute, Newcastle University). The JWMDRC Biobank, was established in 2008 and comprised one the five core activities of the MRC Centre for Neuromuscular Diseases aimed at supporting the translational program of the centre. The main objective of the biobank is to provide well characterized, high quality biomaterials such as muscle, cell lines, DNA, RNA, plasma, serum, urine and CSF of patients with neuromuscular disorders to researchers within the centre and the wider scientific community. Currently, the JWMDRC Biobank has assembled a collection of more than 17,000 anonymised rare disease samples mostly derived from NMD patients. In 2010, the Biobank was recognised as an official member of EuroBioBank (http://www.eurobiobank.org/en/information/info_institut.htm) and has applied quality criteria and standard operation procedures in accordance with EuroBioBank protocols. | |
| The Katharine Dormandy Coagulation Research Plasma Bank | Greater London | The Katharine Dormandy Coagulation Research Plasma Bank is a collection of blood samples that can be used in research to better understand blood coagulation or clotting. Instead of collecting samples from patients for individual projects, the plasma bank enables us to create a ‘library’ of samples from patients with different types of problems with their blood clotting. The Haemophilia Centre at the Royal Free Hospital is a centre of excellence and sees large numbers of patients with both inherited and acquired coagulation disorders affecting the process by which blood forms a clot. The plasma bank allows on-going research into the underlying causes of these disorders, tests to allow the prediction of the severity of the disorder, tailoring treatment to individual patients and validation of new laboratory tests. All projects will have been approved by a panel of experts. Results of the research performed will be presented at national and international conferences and submitted for publication in appropriate journals. The aim of all research is to be able to provide the best care possible to patients with clotting disorders. | |
| The National Epithelioid Haemangioendothelioma (EHE) Biobank | Greater London | The National Epithelioid Haemangioendothelioma (EHE) Biobank supports research in this very rare form of vascular sarcoma. Funded by the EHE Rare Cancer Charity, the National EHE Biobank has been jointly created by the Institute of Cancer Research (ICR) and the Royal Marsden Hospital (RMH) in London. The creation of this biobank allows access to clinical EHE samples which is a key component in our overall research strategy, ultimately leading to our ability to treat the disease. | |
| The National Gastrointestinal Stromal Tumour (GIST) Biobank | Greater London | The National GIST Biobank supports research into gastrointestinal stromal tumours with the overall aim of improving diagnostic accuracy, identify new drug targets and develop new tests to predict or monitor response to treatment. | |
| The Nottingham Bioresource | Nottinghamshire | The Nottingham Bioresource consists of a broad range of samples, including but not limited to tumour tissue, adjacent normal tissue, various biological fluids such as serum, plasma, whole blood urine and saliva. The collection is stored in -80 freezers, in formalin fixed paraffin embedded blocks (FFPE)and slides. There is an additional collection of blood and saliva from coronavirus positive patients at our satellite site. The Bioresource prospectively collects samples tailored to the academic need. Clinical data is obtained only as necessary to enhance the scientific value of the samples for research. Full informed consent is in place for all samples in the Bioresource. | |
| The Oxford Biobank | Oxfordshire | The Oxford Biobank is a local Oxfordshire cohort of participants who have given informed consent to be re-approached for further targeted translational studies, such as recall-by-genotype or recall-by-phenotype studies. The Oxford Biobank consists of random healthy participants (n=8000), patients with type 2 diabetes (n=800), and a recently established work place based COVID-19 research cohort. | |
| The PEACE Study | Greater London | The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study | |
| The PNH Research Tissue Bank | West Yorkshire | A research tissue bank for patients with Paroxysmal Nocturnal Haemoglobinuria | |
| The Queen Square Brain Bank for Neurological Disorders | Greater London | The Queen Square Brain Bank for Neurological Disorders(QSBB) holds a unique archive of brains and tissue donated by individuals with neurodegenerative disease and neurologically normal controls. It specialises in parkinsonian movement disorders, including Parkinson's disease and multiple system atrophy and holds the national collection of brains donated by individuals with progressive supranuclear palsy. The collection has been developed to include donated brains from prospectively studied people with familial dementias, in collaboration with the Dementia Research Centre at The National Hospital for Neurology and Neurosurgery. The QSBB also banks brains donated by people with dystonia. | |
| The Robert Lane Tissue Bank | Greater London | The Robert Lane Tissue Bank is a Genito-Urinary tissue bank collecting and storing samples of prostate, testis, penile, kidney and bladder cancer. It consists of fresh frozen and formalin fixed tissue samples as well as whole blood, plasma and serum collected from patients with Genito-Urinary cancers or being investigated for malignancy. The bank was set up with the purpose of expanding the collection of male-specific cancers; providing material for scientific research aiming to discover new biomarkers that have the potential to be used as diagnostic/prognostic markers. Ultimately, this could assist in creating personalised treatments for patients. In addition to our own in-house research we have collaborations with groups within the UK, in the EU and USA. | |
| The Swansea Neurology Biobank | Cardiff | The Swansea Neurology Biobank, (SNB) is a collaboration between Swansea University and Local Health Boards, collecting biological specimens from a range of neurological phenotypes. | |
| Tissue Access for Patient Benefit (TAPb) | Greater London | We aim to facilitate the pathway for access, storage, use and transfer of human organs, cells and tissue between clinical centres within UCL Partners, academic groups in UCL, other universities, hospitals, medical researcher and biotechnology companies, to enhance the ability for researchers to access the materials they need. Alongside this, researcher will be able to exchange information and access guides on regulatory, ethics and practical issues concerning access, transfer and use of this type of material. These guides will be video and documents format, based on talks at organised events given by experts in the relevant fields. | |
| Tissue Solutions Ltd | Glasgow (City of) | Tissue Solutions specializes in sourcing biological material for academics, pharma & biotech companies and CROs and is working with clients worldwide (USA, UK, Europe and Japan). We are a virtual tissue bank, working with multiple sources to acquire samples on behalf of our clients for use mainly during the preclinical research phase. We never retain tissues ourselves for our own use. We provide access to banked human tissues and set up prospective collections in the UK and USA. We specialise in sourcing "tough" tissues, eg fresh samples or those with specific inclusion and exclusion criteria. We provide both diseased and non-diseased samples, FFPE and fresh frozen and fresh samples. | |
| TNT: Triple Negative breast cancer Trial | Surrey | TNT is a phase III, multi centre, randomised trial of carboplatin versus docetaxel in women with ER-, PgR- and HER2- metastatic or recurrent locally advanced breast cancer. Patients will be randomised (1:1) to carboplatin or docetaxel and will cross over to the alternative treatment (docetaxel (if randomised to carboplatin) or carboplatin (if randomised to docetaxel)) on progression. Trial Treatment: Group A: Carboplatin AUC 6, q 3 weeks for 6 cycles (18 wks) Group B: Docetaxel 100mg/m2, q 3 weeks for 6 cycles (18 wks) On evidence of disease progression, patients will cross over to the alternative treatment. | |
| Tommy's National Reproductive Health Biobank | West Midlands | The Tommy's Biobank aims to prospectively collect samples and data from pregnant and non pregnant women,their partners and baby, to help research in to pregnancy complications. The biobank has been granted permission to ethically approve research projects conducted in the field of reproductive health. The biobank has six tissue collection centres which work together to fulfil sample and data requests from researchers. We have obtained approval to collect: 1-Endometrium 2-Myometrium 3-Placenta,cord, cord blood 4-Urine 5-Maternal blood 6-Amniotic fluid 7-Vaginal Swabs 8-Omentum 9-Subcutaneous Fat 10-Buccal Swab 11-Breast Milk Samples from father: 1-Buccal Swab 2-Urine 3-Blood Samples from 1 week old baby 1-Urine 2-saliva 3-Buccal swab 4-meconium (stool) 5-Stool Current Collections: 1- Myometrium from pregnant women who have undergone caesarean section or have had hysterectomies. 2-Endometrium from recurrent miscarriage patients (Frozen,FFPE) 3-DNA (Whole blood) from recurrent miscarriage patients | |
| TOPARP: Ph. II Trial of Olaparib in Patients with advanced CRPC | Surrey | TOPARP is an open-label, single arm, two part adaptive design phase II trial of olaparib in mCRPC. Patients will receive single agent olaparib at a dose of 400 mg twice daily, continuously on a 28-day cycle, until objective disease progression or unacceptable toxicity or patient withdrawal for whatever reason. | |
| TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy (Rx)) | Greater London | A prospective observational cohort study of patients with non-small cell lung cancer (NSCLC), in which translational research is the fundamental aspect of the study. | |
| TransATAC tissue core and DNA research bank | Greater London | The TransATAC tissue core and DNA research bank (TA RTB) securely houses the human tissue taken, stored, and used in the ATAC (LATTE) trial (trial n. 1033L/0029). It is a retrospective collection with no plans for further tissue collection. Its purpose is to support research into proteins and genetic markers identified by current research as potentially having a role in breast cancer. | |
| TransRAMPART | Greater London | TransRAMPART is the translational research study being run alongside the RAMPART trial. The study involves the collection of blood, urine and tumour tissue samples at various time points throughout patient follow-up. | |
| TRICON8 | Cambridgeshire | TRICON8 is the translational research sub-study of the ICON8 trial. Its aim is to establish a large, comprehensive biobank comprising tumour tissue, blood and serial plasma samples with associated clinical data which will be an invaluable resource for high-quality translational research in ovarian cancer. ICON8 is a phase III randomised controlled trial designed to investigate the safety and efficacy of two dose-dense, dose-fractionated, weekly carboplatin-paclitaxel combination chemotherapy regimens for the treatment of newly diagnosed ovarian cancer compared to standard three-weekly carboplatin-paclitaxel. There is a growing body of evidence that using dose-fractionated paclitaxel in particular may have increased anti-tumour effects, and this is thought to be due to enhanced anti-angiogenic and pro-apoptotic effects. | |
| TRICON8B | Cambridgeshire | TRICON8B is the translational research sub-study of the ICON8B trial. The aim is to establish a large, comprehensive biobank comprising tumour tissue, blood and serial plasma samples with associated clinical data which will be an invaluable resource for high-quality translational research in ovarian cancer. ICON8B is a phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer. | |
| TwinsUK | Greater London | TwinsUK is the UK’s largest adult twin registry and the most clinically detailed in the world. Set up the cohort in 1992 to investigate the incidence of osteoporosis and other rheumatologic diseases in several hundred monozygotic (identical) twins. We now have over 15,000 identical and non-identical twins from across the UK, with ages between eighteen and one hundred and our research has expanded to include multiple diseases and conditions. TwinsUK aims to investigate the genetic and environmental basis of a range of complex diseases and conditions. Current research includes the genetics of metabolic syndrome, cardiovascular disease, the musculoskeletal system, ageing, sight as well as how the microbiome affects human health. The TwinsUK cohort is now probably the most genotyped and phenotyped in the world. TwinsUK data have enabled multiple collaborations with research groups worldwide and the publication of over 700 research papers. | |
| UCB Research Tissue Bank | Berkshire | This is an industy based repository of frozen PBMC from healthy volunteers donating blood through NHS-BT | |
| UCL / UCLH Biobank for Studying Health and Disease | Greater London | The Biobank stores normal and pathological specimens, surplus to diagnostic requirements, from relevant tissues and bodily fluids. Stored tissues include; snap-frozen or cryopreserved tissue, formalin-fixed tissue, paraffin-embedded tissues, and slides prepared for histological examination. Tissues include resection specimens obtained surgically or by needle core biopsy. Bodily fluids include; whole blood, serum, plasma, urine, cerebrospinal fluid, milk, saliva and buccal smears and cytological specimens such as sputum and cervical smears. Fine needle aspirates obtained from tissues and bodily cavities (eg. pleura and peritoneum) are also collected. Where appropriate the Biobank also stores separated cells, protein, DNA and RNA isolated from collected tissues and bodily fluids described above. Some of the tissue and aspirated samples are stored as part of the diagnostic archive. | |
| UCL BioResource | Greater London | The UCL BioResource is a genetics research registry that obtains samples as well as basic demographic and phenotypic details on patients and healthy volunteers. The majority of participants are also genotyped. This facilitates recall of volunteers, use of samples, or use of data based on phenotypic and/or genotypic criteria. | |
| UCL Eastman Biobank | Greater London | The UCL Eastman Biobank will act as a physical repository for collections of biological samples and data for research purposes from consented patients at the Eastman Dental Institute and Hospital, University College London and University College London Hospitals Foundation Trust (Eastman). This will incorporate prospective collections of stored samples and new collections. It provides a unique opportunity to advance dental and medical research by making access to tissue surplus to requirements easier, and more efficiently, and with a high level of governance compliant with HTA standards. The Biobank will support projects principally involved in the study of human disease and the normal functioning of the human body. The Biobank will store normal and pathological specimens from relevant tissues and bodily fluids. Tissue will be stored in a variety of formats. The establishment of a core programme will enable a centralised approach to the management and integration of all research groups working within these institutions, providing appropriate structure and support. | |
| UCL Infection DNA Bank | Greater London | The UCL Infection DNA Bank aims to facilitate research into infectious diseases through the enhanced availability of samples to researchers. This availability currently supports research in the UCL Division of Infection and Immunity but it will also support researchers nationally and internationally, increasing the potential for collaboration. | |
| UCL Institute of Ophthalmology Biobank | Greater London | The biobank is a collection of tissues donated as a resource to doctors and researchers for the purpose of medical research into the causes of blindness and eye disease. | |
| UCL Royal Free Hospital Biobank | Greater London | The physical repository was established in Nov 2009 and is located within the Royal Free London NHS Trust, London UK. The UCL-RFH Biobank provides a biorepository facility to user groups on a cost-recovery model. Types of biospecimens include Serum, Plasma, Cells, Tissue, DNA, Urine etc. In particular, samples considered 'relevant material', such as tissues and cells, which are licensed by the Human Tissue Authority (HTA), can be stored long term. Existing holdings where appropriate can be transferred to the BioBank at the Royal Free Campus. The physical repository has a planned onsite capacity of 1 million samples. Samples can be stored at -80’C in mechanical freezers or -180’C in vapour phase liquid nitrogen, in either 1ml or 2ml cryotubes. The Biobank is licenced by the HTA (substantive licence No. 11016) and is a satellite site of the clinical transplant laboratory (Centre for Cell, Gene and Tissue Therapeutics) based at the Royal Free Hospital. Over the past 5 years, the demand for the biobank’s facility has increase exponentially, increasing between 50%-100% year on year. The biobank currently provides biorepository facilities to 46 user groups who collectively have stored 200,000 aliquots. | |
| UK Biobank | Cheshire | UK Biobank is a major national health resource, and a registered charity in its own right, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis, detailed information about themselves and agreed to have their health followed. Over many years this will build into a powerful resource to help scientists discover why some people develop particular diseases and others do not. | |
| UK CLL Trials Biobank | Lancashire | A collection of Chronic Lymphocytic Leukaemia samples from patients on clinical trials. Includes the trials; AdMIRE, ARCTIC, CHOP-OR, CLL210, CLEAR, COSMIC, RIAltO, FLAIR | |
| UK ME/CFS Biobank | Greater London | Participants: Over 650 participants are included in the study, including ME/CFS participants diagnosed by a physician and compliant with CDC ’94 (Fukuda) and Canadian Consensus Criteria (CCC), with case definition compliance available for four other commonly-used criteria. Healthy and MS matched controls are also available. • Mild and Moderate ME/CFS • Severe (Home-Bound) ME/CFS • Multiple Sclerosis • Healthy Controls Samples Available: Over 32,000 aliquots available. • Whole Blood • Serum • Plasma • RBCs • PBMCs (Sodium Heparin and K2 EDTA) • Blood for RNA Extraction (PaxGENE) Associated Data Available: • Baseline Standard Laboratory Tests to exclude comorbidity causes of fatigue • In-person clinical assessment data • Detailed Symptoms Assessments • Demographic information • Standardised instruments of Fatigue Severity and Functional Impairment | |
| UK MND Collections | Northamptonshire | The UK MND Collections (formerly known as the UK MND DNA Bank) was established to provide the international research community with a resource that would help to identify and understand the causative and disease modifying factors involved with motor neurone disease. These samples are available for research into MND and associated conditions such as fronto-temporal dementia only. The UK MND Collections combines more than 3,000 biological samples and accompanying clinical information; as well as epidemiology data from 400 participants, including people with MND, controls and family members. The DNA Bank was the original Collection of whole genome DNA from over 3,000 blood samples, which are stored at CIGMR (Centre for Integrated Genomic Medical Research) in Manchester, UK. The DNA Bank also has clinical information (divided into a minimum and extended dataset) which is available to researchers. The Cell Lines Collection offers a sub set of the DNA Bank samples as EBV-transformed lymphoblastoid cell lines and peripheral blood lymphocytes. This was originally set up as an everlasting supply of DNA, with the lymphoblastoid cell lines now available to researchers to help them understand how the disease is developing. The Epidemiology Collection has just over 200 patient and matched control blood samples with extensive environmental and lifestyle data (both from self-report questionnaires and telephone interviews) available to researchers. More information on the DNA and cell bank is available in Smith et al BMC Genetics (2015) 16:84. | |
| UK primary Sjogren's syndrome Registry | Northumberland | Peripheral blood samples (DNA, RNA, serum, PBMC) from patients with primary Sjogren's syndrome, with detailed contemporaneous clinical data at the time of sample collection. | |
| UK real-world lymphoid tissue bank | Hampshire | The UK real-world lymphoid malignancies tissue Bank (UKTB) provides a national and international resource for research on lymphomas and other lymphoproliferative disorders including chronic lymphocytic leukamia. This Research Tissue Bank was set up in 2014 and given favourable ethical opinion (REC ref: 14/SC/0030). The samples are stored in the HTA licenced Faculty of Medicine Tissue Bank. The RTB currently holds matched normal and malignant frozen material from ~900 patients. The samples collected can be associated with clinical diagnostic details and outcome endpoint, which can be readily informative to patient prognosis. | |
| UKALL14 Trial | Greater London | A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia. Multisite, randomised controlled trial, recruiting 811 patients over 7.5 years. Samples will be collected throughout the trial and sent to the central lab (Adult ALL MRD Lab @ UCL CI) as follows; - bone marrow samples taken at diagnosis, at recover post phase 1 and phase 2, post transplant (for those patients who proceed with a non-myeloblative transplant) and at relapse. - pheripheral blood sample taken during phase 1 on days 4 & 18 (in patients 40 and under) and on D18 & 32 in patients 41 or over), and during intensification. Additionally for those patients who proceed for a non-myeloblative transplant peripheral blood will be sent to the local chimerism labs and a copy of the report will be sent to UCL CTC. | |
| Ukall60 Trial | Greater London | The UKALL60+ trial is a multi-centre, prospective, non-randomised, multiple pathway trial to document the safety, tolerability and efficacy of standard ‘backbone’ chemotherapeutic regimens in older patients with de novo ALL. Samples will be collected throughout the trial and sent to the central lab (Adult MRD lab at UCL CI) as follow: 1. At diagnosis (pre trial registration) 2. After Phase 1 Induction 3. After Phase 2 Induction 4. a) After Intensification (for patients on the pathway B ONLY) b) After Consolidation 1 (Pathways A, C & D) An additional bone marrow or peripheral blood sample is also sent to the MRD lab if the patient relapses. This sample should be from the routine sample taken to diagnose relapse. | |
| UKCTOCS Longitudinal Women's Cohort (UKLWC) | Greater London | This is the bioresource resulting from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), one of the world’s largest randomised controlled trials. Between 2001-2005 1.2 million women aged 50-74 years were invited from the general population and 202,638 post-menopausal were randomised (2:1:1) to routine care, or annual CA125 blood testing (7-11 rounds) or ultrasound to evaluate the impact of ovarian cancer screening on disease mortality. All participants provided a serum sample at recruitment with 50,262 providing further longitudinal annual samples (median of 9 samples). Women were free of any active malignancy at enrolment (2001-2005). During the follow-up period of >15 years to-date a proportion of those have subsequently developed a number of different diseases. Available comprehensive electronic health record linkage of the cohort’s participants (including Hospital Episode Statistics (HES); ONS (Cancer registry, Death Certificates); National Cancer Intelligence Network (NCIN); and Myocardial Ischaemia National Audit Project (MINAP) allows exploiting clinical phenotyping and diseases diagnoses made during routine healthcare in the NHS. Women were also sent postal questionnaires. Secondary studies have to date generated additional data on symptoms, menopause and its management and further details of individual cancers. The biobank contains >540,000 high-quality serum samples (10 x 500μL aliquots in straws), composed of baseline (from >189,000 women) and a unique longitudinal set of >350,000 annual serial samples (median 9) (from approximately 50,200 women). Samples have already been validated for multi-omics analysis with academic and commercial collaborators in nested case/controls sets used for genotyping, proteomics (including SWATH technology), methylation, NMR metabolomics, autoantibody profiling, ELISA-based assays, lipidomics and miRNA. All data is stored in the IG Toolkit-compliant and ISO 27001:2013-certified UCL Data Safe Haven. All samples from the biobank have been collected using a standardised protocol and stored in liquid nitrogen at HTA licensed facilities at UK Biocentre, Oxford, UK. | |
| UNIRAD UK Sample collection | Surrey | Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease (UNIRAD). | |
| University of Bristol | Bristol | Fully anonymised tooth tissue, some teeth are whole, the majority sectioned into crowns and roots. Very limited number of children's teeth. No donor data | |
| University of Leeds | West Yorkshire | Samples collected from patients in the CALIBER trial of chemoablation versus surgical management in low risk non-muscle invasive bladder cancer | |
| University of Leicester Cancer Research Biobank | Leicestershire | The Biobank collects and stores samples for local studies. Samples collected include; •Frozen disease-affected tissue •Paraffin embedded disease-affected tissue •Blood •Urine •sorted stem cells | |
| University of Liverpool | Merseyside | The Liverpool Blood Diseases Biobank (LBDB) is a Research Tissue Bank (RTB). The aim of the LBDB is to store a range of samples from patients with haemic malignancy to further research within this area, or to further enhance the knowledge of the biology of cancer. The LBDB has a large range of samples from patients primarily with chronic lymphocytic leukaemia (CLL), but also includes samples from patients with mantle cell lymphoma (MCL) and other B-cell non-Hodgkin’s lymphomas (B-NHL). The LBDB will begin collecting and storing samples from patients with Acute Myeloid Leukaemia (AML) and multiple myeloma (MM). The main samples stored within the LBDB are cryopreserved peripheral blood mononuclear cells (PBMCs) which have been purified from blood donated by patients. | |
| University of Liverpool - GCP Laboratory Facility | Lancashire | Combined repository of clinical trial samples for ‘future use’. Will include samples from clinical trials co-ordinated by the Liverpool Cancer Trials Unit and from studies with Liverpool Principal Investigators. | |
| University of Southampton Faculty of Medicine Tissue Bank | Hampshire | The Tissue Bank is licensed by the Human Tissue Authority (HTA) to source, organise, collect, prepare, store and distribute a diverse collection of human tissues and biological products. All tissue is collected with patient consent and distributed anonymously only to National Research Ethics Service (NRES) approved studies. This valuable resource is available to aid the study of cancer biology and other associated research. The Tissue Bank allows for rapid access to a plethora of biological materials supported by an inventory management system. Tissues currently available include normal and malignant snap frozen tissue, FFPE blocks, fresh biopsy tissues, blood products and biological fluids. Collections are organized by Tissue Bank staff and include a wide variety of cancer classifications. The Tissue Bank currently holds over 100,000 vials. | |
| URoBank: Urothelial Research Tissue Bank | North Yorkshire | URoBank is a small repository for tissue samples collected surgically representing both normal urinary tract tissues (urethra, bladder, ureter, renal pelvis and kidney) and urological disease states (benign and cancer). Other normal epithelial tissues of relevance to urological practice (for example buccal mucosa which is used in urethral reconstruction) and/or comparative purposes (e.g. as controls for understanding urothelial tissue-specificity) are held as a subset. These tissues have primarily been harvested as biopsies and processed routinely into paraffin wax, in general there are only small amounts of tissue remaining. Our collaborating tissue collection centres include Pinderfields Hospital, James Cook University Hospital, York Hospital, Leeds Teaching Hopital NHS Trust and Royal Manchester Children's Hospital. | |
| VAMP Tissue Bank | Cambridgeshire | The purpose of the research tissue bank is to provide fresh human biological samples for research. There is a current unmet need to provide anonymised fresh human biological samples to researchers undertaking clinical research across the Cambridge Biomedical Campus. This research protocol seeks to establish a panel of healthy volunteers who will consent to provide anonymised human biological samples on an ad hoc re-call basis for use by third party researchers associated with the Cambridge Biomedical Campus for clinical research purposes (University of Cambridge, NHS, Biopharma and Biotech employees and collaborators). No information will be fed back to volunteers, other than which organization the biological sample is being provided to. | |
| Vasculitis and Inflammation Integrated Research Tissue Bank (VII RTB) | West Yorkshire | Collection of samples from individuals with different types of vasculitis (especially giant cell arteritis, large vessel vasculitis and polymyalgia rheumatica), autoantibody-mediated diseases, inflammatory diseases such as Behçet's syndrome, Takayasu's arteritis or IgG4-related disease. A number of control samples from healthy individuals or those with different inflammatory or non-inflammatory vascular diseases or infections are also held. | |
| VinCaP | Greater London | VinCaP is a phase II, multicentre, non-randomised trial of Vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the Penis. 22 evaluable participants will be recruited from 9 centres and all patients will receive 4 cycles of IV vinflunine 320mg/m2 on day 1, to be repeated at intervals of 21 days. The primary endpoint, determined by RECIST v1.1, is clinical benefit (objective response + stable disease rate) measured after four cycles of vinflunine chemotherapy. Secondary endpoints are objective response rate (CR+PR), toxicity, progression-free survival, overall survival and treatment compliance. Formalin fixed paraffin embedded (FFPE) tumour blocks are held at the Orchid Tissue Laboratory and Barts and The London School of Medicine and Dentistry. | |
| Virus Watch: Understanding community incidence, symptom profiles, and transmission of COVID-19 | Greater London | Virus Watch is a household community cohort study of acute respiratory infections in England & Wales and will run from June 2020 to Sept 2021. The study aims to recruit 50,000 people, including 12,500 from minority ethnic backgrounds, for an online survey cohort. Nested within this larger study will be a sub-cohort of 10,000 individuals, including 3,000 people from minority ethnic backgrounds. This cohort of 10,000 people will have full blood serology taken between October 2020 and January 2021 and repeat serology between April and July 2021. Participants will also post self-administered nasal/throat swabs for PCR assays of SARS-CoV-2 and will follow one of three different PCR testing schedules based upon symptoms. | |
| VIVO Biobank | Tyne and Wear | As a partnership between Cancer Research UK and Blood Cancer UK (formerly Bloodwise), VIVO Biobank provides a single point of access for people and organisations involved in researching blood, bone marrow and solid cancers in the young. VIVO Biobank merges the two existing national biobanks focused on childhood and youth cancer research – the CCLG Tissue Bank and CellBank. It contains all of the samples stored in each, making a deeper pool of tissues available from a single point of access. VIVO Biobank creates an integrated approach to how cancer samples are collected, stored and catalogued. It helps simplify how samples and data can be accessed by the research community and opens possibilities to link that data with other databases more easily. VIVO Biobank is open to international as well as UK-based researchers. Applications are reviewed rapidly by an independent sample and data access committee. Our team can give help and advice at all stages of the application from initial enquiry to dispatch of samples. VIVO Biobank also holds a collection of HLA-typed cord blood which are subject to the same review process. | |
| Wales Cancer Biobank | Cardiff | The Wales Cancer Bank (WCB) was set up in 2004 and consented the first patient in 2005. The project is hosted by Cardiff University and receives funding from the Welsh Government, Cancer Research Wales and Velindre Charitable funds. A Cancer Bank is literally a collection of tissue and blood which has been collected from patients where cancer is a possible diagnosis and is being stored to facilitate future research into cancer. Statistics suggest that four out of ten people will be diagnosed with cancer at some point during their life. Cancers are complex diseases and it is an on-going quest to understand how they develop, spread and can be treated. The development of more effective, targeted treatment for cancer depends on increased understanding of the molecular mechanisms involved in the initiation of the tumour, its progression to metastatic disease and response and resistance to treatment. Research studies rely on the availability of high quality biological material from patients with cancer and large studies are needed to correlate biology with clinical outcome. The Welsh population is relatively stable and this makes it an ideal cohort to collect and study. Linkage with the all Wales cancer clinical database (CANISC) enables good correlation of science with clinical follow-up. This will eventually enable the results from hundreds of research projects to be integrated and linked to clinical outcome and this will be an invaluable source of data for bioinformatics specialists to examine. All the data collected is being stored on a database housed in the NHS to ensure security and confidentiality The WCB currently consents patients in 12 hospitals around Wales with specially trained research nurses and clinical teams. | |
| Wales Kidney Research Tissue Bank | Cardiff | The purpose of The Wales Kidney Tissue Bank is to serve as a repository of samples donated by patients and normal volunteers for use in studies advancing the understanding of and care for kidney diseases. | |
| Watch and Wait Trial | Greater London | Watch and Wait is a randomised phase III trial to determine whether initial treatment with rituximab in patients with advanced stage asymptomatic follicular lymphoma (grades 1, 2 and 3a) results in a significant delay in the initiation of chemotherapy or radiotherapy and the impact of each strategy on patient-related quality of life. 360 patients randomised to receive either Rituximab treatment and maintenance or to a Watch and Wait strategy. Samples collected for trial: Formalin fixed paraffin embedded tumour block or unstained slides (lymph node and bone marrow)- sent to HMDS. Blood and bone marrow sample taken at baseline and if patient in CR clinically and radiologically at 7, 13 and 25 months - sent to University College London Hospital | |
| West Midlands Covid 19 Digital Collaboration Biobank | West Midlands | 61847 covid 19 samples stored (5926 donors) - serum -plasma -covid 19 swabs - elutions Data: Full demographics to match the samples collected | |
| York Tissue Bank | North Yorkshire | In collaboration with York and Scarborough Teaching Hospitals NHS Foundation Trust, the University of York has established the York Tissue Bank: a tissue bank to help research into human disease. We aim to collect, store and build a repository of human tissue samples, such as urine, blood and tumours. These can then be given to researchers for their studies. These studies will aim to improve our understanding of human health and potentially lead to new methods of diagnosis, better treatments and vaccines for a wide range of diseases. We rely on participants to voluntarily gift their tissue samples for this vital future research. Our Bioresource is described in detail here: https://openbioresources.metajnl.com/articles/10.5334/ojb.49/ |